BR112021004865A2 - use of the fungicide isoflucypram to control claviceps purpurea and reduce sclerotia in cereals - Google Patents

Abstract

"USE OF ISOFLUCYPRAM FUNGICIDE TO CONTROL CLAVICEPS PURPUREA AND REDUCE SCLEROCE IN CEREALS". The present invention relates to the use of the fungicide Isoflucypram, to control Claviceps purpurea on cereal plants, plant parts thereof, plant propagation material or the soil in which the cereal plants are grown or intended to be grown, to a method of treating plants or plant parts to control Claviceps purpurea and a seed treatment method of controlling Claviceps purpurea in seed and in plants growing from the seed by treating the seed with the fungicide Isoflucypram.

Description

Invention Patent Descriptive Report for "USE OF THE

ISOFLUCYPRAM FUNGICIDE TO CONTROL CLAVICEPS PURPUREA AND REDUCE SCLEROCIUM IN CEREALS".

[0001] The present invention relates to the use of the fungicide Isoflucypram to control Claviceps purpurea and reduce sclerotia in cereals, to a method of treating cereal plants, plant parts thereof, to control Claviceps purpurea and reduce sclerotia in these plants of cereals.

[0002] Claviceps purpurea is the fungus that causes the so-called ergot (ergot) in grasses such as rye and ryegrass (main economic hosts), barley, oats, triticale, wheat and other cultivated and wild grass species in the Pooideae subfamily , including agrostide (bentgrass), Agrostis (bluegrass) and fescue (fescue). Claviceps purpurea is unique in that the fungus infects only the ovaries of the host plant. During infection of the host plant, the plant's ovary is replaced by a blackened sclerotia, often called the ergot or ergot body. Sclerotia are the spores form of the fungus during the winter season, which will be partially collected with the harvest and partially fall to the ground. The sclerotia will need a vernalization period of about four to eight weeks at temperatures between 0 and 10 degrees Celsius to break the dormancy and germinate. The sclerotia consists of whitish mycelial tissue containing storage cells and a dark pigmented outer cortex that protects the fungal mycelium from desiccation, ultraviolet light, and other adverse environmental conditions. Due to their unique mode of infection, open-pollinated cereal species are highly susceptible to infection, in particular rye and triticale.

[0003] The main problem of the disease is, besides the reduction of yield, the toxic alkaloids of the sclerotia that cause serious health problems in both animals and plants. Outbreaks of en-

poisoning is called ergotism and has been described in the middle age, where the consumption of ground rye seed meal contaminated with ergot bodies caused gangrene, mental hallucinations and convulsions.

Claviceps purpurea infection benefits from cooler and wetter climatic conditions during the flowering period of the cereal plant.

The disease is controlled through different techniques, such as cleaning seeds, planting clean seeds, cleaning the edges of the field and controlling weeds, rotating crops or deep plowing.

To determine disease severity, normally the amount of sclerotia / ergot bodies is assessed in the grain, as it is very difficult to assess disease in the early stages of infection.

The evaluation of the amount of molasses produced by the fungus during the infection is not predictive of the amount of sclerotia present in the grain.

Consequently, the presence of sclerotia also called ergot or ergot bodies in harvested grains of different types is a classification factor, for example, in the Official Grain Guiding Guide of Canada. Low ergot levels, on the other hand, will lead to grain degradation, particularly in higher quality grains such as registered, certified or genetic-type high quality grades.

In grains intended for human and animal consumption, such as rye or wheat, tolerance levels are much lower than in grains not consumed by humans or animals, such as forage grass.

For forage grasses, a maximum of 3% ergot bodies in seed, ie up to 3 ergot bodies per 100 seed cores (Basic / Registered / Certified / Common) is tolerated.

For wheat grains intended for human and animal feed, the limit is much lower, at 0.04% by weight.

However, fungicides capable of controlling Claviceps purpurea that would solve the underlying problem in a highly efficient way are rare.

Until now, azoxystrobin or propiconazole has been labeled for use against ergot in the Pacific Northwest. Recently, a study described the use of eight different fungicidal products (azoxystrobin / propiconazol, boscalide, dichloran, fluazinam, fluopyram / prothioconazole, pentachloronitrobenzene, picoxystrobin / cyproconazole, fluxapyroxad / pyraclostrobin as soil-applied fungicides in perennial herbs , 106 (2018), pp 146-149) with the aim of finding a more environmentally sustainable solution in perennial grasses to eliminate bodies of ergot from the ground rather than open field burning. In addition, in many annual cereal production areas, perennial grasses are grown in ditches, roadsides and riparian areas to stabilize soils on steep slopes and thus prevent soil erosion. As many forage grass species are susceptible to ergot, these areas act as a perennial reservoir of ergot inoculum, which infects cereal crops annually. Furthermore, in controlling ergot bodies in grains harvested from classical cereals such as rye, barley, wheat intended for human or animal consumption, a significantly greater degree of control is required. In particular, in hybrid cereals such as hybrid wheat, there is a great need to control Claviceps and prevent the formation of ergot bodies as sterile male plants flower for a longer period of time and are therefore more susceptible.

[0004] There is therefore an urgent need for fungicides that allow sufficient control of Claviceps purpurea in cereal plants.

[0005] WO 2010/130767 and EP 3000809 A1 disclose fungicidal pyrazole carboxamide derivatives, for example isoflucypram, i.e. N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5- fluoro-1-methyl-1H-pyrazole-4-carboxamide (Example 29), which are used with

tra different fungi. However, it is not apparent from the teaching in the publication which specific pyrazole carboxamide fungicides are suitable for the treatment of Claviceps purpurea. More particularly, neither WO 2010/130767, EP 3000809 A1 nor any other document explicitly describe the suitability of Isoflucypram for controlling Claviceps purpurea and/or reducing sclerotia. Even more particularly, neither WO 2010/130767 nor any other document explicitly discloses the suitability of Isoflucypram for controlling Claviceps purpurea in cereal plants and/or reducing sclerotia using foliar application.

[0006] WO 2017/194363 discloses ternary fungicidal combinations comprising (A) fenpicoxamide, (B) isoflucypram and (C) another compound selected from prothioconazole, fluopiram and tebuconazole. WO 2017/194363 discloses that said ternary combinations are particularly suitable for controlling specific cereal diseases, wherein said cereal diseases are caused by Mycosphaerella sp., Puccinia sp., Leptosphaeria sp., Pyrenophora sp., Ramularia sSp ., Gaeumannomyces sp., Fusarium sp., Giberella sp. Monographella sp., Septoria sp., Cochliobolus sp. and Rhynchosporium sp.. However, WO 2017/194363 does not explicitly disclose and does not show that said ternary combinations are effective against Claviceps purpurea in cereals. More particularly, WO 2017/194363 does not disclose the suitability of Isoflucypram for controlling Claviceps purpurea in cereal plants and/or reducing sclerotia in cereal plants using foliar application.

[0007] It has now been found that, surprisingly, the fungicide Isoflucypram is particularly suitable for the control of Claviceps purpurea and/or for the reduction of Claviceps purpurea sclerotia in cereal plants, plant parts thereof, plant propagation material or the soil in which cereal plants are grown or are intended to be cultivated. It has also been found that the use of Isoflucypram is particularly suitable for controlling Claviceps purpurea and for the reduction of Claviceps purpurea sclerotia in hybrid cereals, in particular hybrid wheat and in the production of hybrid wheat seed. Isoflucypram was found to be able to control Claviceps purpurea and reduce Claviceps purpurea sclerotia in cereals, in particular in hybrid cereals such as hybrid wheat and in hybrid wheat seed production, at a surprisingly low dose rate. . Isoflucypram was found to be able to control Claviceps purpurea using foliar application.

[0008] The use of Isoflucypram for the control of Claviceps purpurea and/or for the reduction of Claviceps purpurea sclerotia in hybrid wheat proved to be particularly advantageous.

[0009] In an alternative embodiment of the invention, combinations comprising Isoflucypram and another fungicide can be used to control Claviceps purpurea in cereal plants.

[0010] The present invention, therefore, presents the use of the fungicide Isoflucypram to control Claviceps purpurea and/or to reduce Claviceps purpurea sclerotia. In another modality, the use of the fungicide Isoflucypram in hybrid wheat production methods for control of Claviceps purpurea and/or reduction of sclerotia of Claviceps purpurea is described.

[0011] Isoflucypram has the chemical name N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazol-4-carboxamide and is a compound according to formula (1) o FF

STE FO (1), a and adequate processes for its preparation, coming from materi-

Commercially available starting materials are described in WO 2010/130767, WO 2014/060518.

[0012] Isoflucypram and/or the other compounds used in the present invention may be present in the form of different stereoisomers. These stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. Thus, the invention encompasses pure stereoisomers and any mixture of these isomers. When a compound may be present in two or more tautomeric forms in equilibrium, reference to the compound by means of a tautomeric description is to be considered to include all forms of the tautomer.

The isoflucypram and/or the other compounds used in the present invention may be present in the form of the free compound and/or an agrochemically active salt thereof.

[0014] Agrochemically active salts include acid addition salts of inorganic and organic acids, as well as salts of usual bases. Examples of inorganic acids are hydrohalic acids such as hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulfuric acid, phosphoric acid and nitric acid, and acidic salts such as sodium bisulfate and potassium bisulfate. Useful organic acids include, for example, formic acid, carbonic acid and alkanoic acids such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, in addition to glycolic acid, thiocyanic acid, lactic acid, succinic acid, citric acid, acid benzoic, cinnamic acid, oxalic acid, saturated or mono- or di-unsaturated fatty acids having 6 to 20 carbon atoms, alkylsulfuric monoesters, alkylsulfonic acids (sulfonic acids having straight or branched chain alkyl radicals having 1 to 20 carbon atoms carbon), arylsulfonic acids or aryldisulfonic acids (aromatic radicals, such as phenyl and naphthyl, which contain one or two sulfonic acid groups),

alkylphosphonic acids (phosphonic acids with straight or branched chain alkyl radicals having 1 to 20 carbon atoms), arylphosphonic acids or aryldiphosphonic acids (aromatic radicals, such as phenyl and naphthyl, which carry one or two phosphonic acid radicals) , where the alkyl and aryl radicals may contain other substituents, for example p-toluenesulfonic acid, salicylic acid, p-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, etc.

[0015] Solvates of isoflucypram or its salts are stoichiometric compositions of the compounds with solvents.

Isoflucypram and/or the other compounds used in the present invention may exist in multiple crystalline and/or amorphous forms. Crystalline forms include unsolvated crystalline forms, solvates and hydrates.

In the context of the present invention, "control of Claviceps purpurea" means a significant reduction in infestation by Claviceps purpurea, compared to the untreated plant, preferably a significant reduction (from 40-79%), compared to the untreated plant (0% reduction in infection); more preferably, Claviceps purpurea infection is totally suppressed (by 70-100%). Control can be curative, that is, for the treatment of already infected plants, or protective, for the protection of plants that have not yet been infected.

In the context of the present invention, "reduction of Claviceps purpurea sclerotia" or "control of Claviceps purpurea" means a significant reduction in the number of Claviceps purpurea sclerotia compared to the untreated plant, preferably a reduction significant (by 40-79%) compared to the untreated plant (0% reduction in infection); more preferably, Claviceps purpurea infection is totally suppressed (by 70-100%). The amount of sclerotia can be measured both pre-harvest and post-harvest in the grain. Control can be curative, that is, for the treatment of already infected plants, or protective, for the protection of plants that have not yet been infected.

[0019] In the context of the present invention, a plant is preferably understood as a plant at or after the leaf development stage (at or after BBCH stage 10 according to the BBCH monograph of the German Federal Biological Research Center for Agriculture and Forestry (German Federal Center for Biological Research for Agriculture and Forestry), 2nd edition, 2001). In the context of the present invention, the term "plant" is also understood to mean seeds or seedlings.

[0020] Cereals are defined as cultivated crops of Poace-ae. In particular, cereals are selected from the group of rye, oats, barley, triticale, wheat (spring wheat or winter wheat), durum. More preferred including barley, rye, triticale, spring wheat, hybrid spring wheat, durum or hybrid winter wheat, hybrid winter wheat.

[0021] Preferably, the wheat is selected to be hybrid spring wheat, durum or hybrid winter wheat, hybrid winter wheat.

[0022] The present invention also refers to the use of isoflucypram for the control of diseases of Gaeumannomyces and/or “maldo-pé”, particularly for the control of Gaeumannomyces graminis. Mal-do-pé is a plant disease caused by Gaeumannomyces graminis that infects plant roots, particularly of grasses and cereals (especially wheat, barley, rye, triticale, durum) and causes symptoms such as yellowing and stunting, reduced growth, blackened roots. Gaeumannomyces graminis also produces extensive damage to the rice sheath, causing black spots and/or discoloration of the plant's foliage.

Uses

[0023] Treatment of plants and plant parts with isoflucypram or compositions containing isoflucypram is carried out directly or acting on the environment, habitat or storage space using customary treatment methods, eg immersion, spraying , atomization, misting, evaporation, dusting, fogging, scattering, foaming, painting, spreading, injection, drenching, drip irrigation and, in the case of propagating material, in particular in the case of seeds, in addition to the dry seed treatment method, the wet seed treatment method, the sludge treatment method, encrustation, coating with one or more layers and the like. Furthermore, it is possible to apply the active substances by the ultra-low volume method or to inject the active substance preparation or the active substance itself into the soil.

[0024] A preferred direct treatment of plants is the treatment of application to the leaves, i.e., isoflucypram or compositions containing isoflucypram are applied to the foliage, it being possible that the frequency of treatment and the application rate are compatible with the pressure of Claviceps purpurea infection in question.

[0025] In the case of systemically active compounds, isoflucypram or compositions containing isoflucypram reach the plants through the root system. In this case, the treatment of the plants is carried out by allowing isoflucypram or compositions containing Isoflucypram to act in the plant's environment. This can be done, for example, by waterlogging, incorporation into the soil or nutrient solution, ie the plant site (eg soil or hydroponic systems) is impregnated with a liquid form of Isoflucypram or compositions containing Isoflucypram, or by application to the soil, i.e. Isoflucypram or compositions containing Isoflucypram are incorporated into the plant locus in solid form (eg in the form of granules).

[0026] More particularly, the use of the invention exhibits the advantages described in cereal plants, plant parts thereof, plant propagation material or the soil in which the cereal plants are grown or are intended to be grown in spray application using compositions containing isoflucypram.

[0027] Combinations of Isoflucypram, with substances including insecticides, fungicides and bactericides, fertilizers, growth regulators, may also find use in the control of plant diseases in the context of the present invention. The combined use of Isoflucypram, with hybrid crops, especially hybrid wheat, is also possible.

[0028] The use of Isoflucypram is preferably carried out with a dosage between 0.001 and 1 kg of Isoflucypram/ha, more preferably between 0.002 and 0.5 kg of Isoflucypram/ha, more preferably between 0.005 and 0.4 kg of Isoflucypram /ha, even more preferably between 7 and 150 g of isoflucypram/ha and most preferably between and 120 g of Isoflucypram/ha. A dosage of from 100 g of Isoflucypram/ha, preferably from 20 to 70 g of Isoflucypram/ha is also disclosed. In another embodiment, the dosage is between 40 and 150 g/ha, preferably between 30 and 120 g of Isoflucypram/ha, more preferably between 25 and 100 g of Isoflucypram/ha, most preferably between 20 and 90 g of Isoflucypram/ha. Formulations

[0029] In one embodiment, fungicidal compositions containing Isoflucypram are described which additionally contain auxiliaries, solvents, vehicles, surfactants or extenders suitable for agriculture.

[0030] According to the invention, a vehicle is a natural or synthetic, organic or inorganic substance with which the active ingredients are mixed or combined for better applicability, in particular for application to plants or parts of plants or seeds. The vehicle, which can be solid or liquid, is generally inert and should be suitable for agricultural use.

[0031] Useful solid vehicles include: for example, ammonium salts and natural rock flours such as kaolin, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth and synthetic rock flours such as finely divided silica, alumina and silicates; Useful solid carriers for granules include: for example, crushed and fractured natural rocks such as calcite, marble, pumice, sepiolite and dolomite, in addition to synthetic granules of inorganic and organic flours and granules of organic material, such as paper, sawdust, coconut husks, corn cobs and tobacco stalks; Useful emulsifiers and/or foamers include: for example, nonionic and anionic emulsifiers such as fatty acid esters - polyoxyethylene, fatty alcohol ethers - polyoxyethylene, for example alkylaryl-polyglycol ethers, alkylsulfonates, alkyl sulfates, arylsulfonates, in addition to protein hydrolysates; suitable dispersants are non-ionic and/or ionic substances, for example, of the alcohol-POE classes and/or - POP ethers, acids and/or POP POE esters, alkylaryl and/or POP POE ethers, lipids and/or POP POE adducts , derivatives of POE- and/or POP-polyol, POE- and/or POP-sorbitan or -sugar adducts, alkyl or aryl sulphates, alkyl- or aryl sulphonates and alkyl or aryl phosphates or the corresponding PO-ether adducts . Further suitable are oligo- or polymers, for example those derived from vinylic monomers, acrylic acid, EO and/or PO alone or in combination with, for example, (poly)alcohols or (poly)amines. It is also possible to use lignin and its sulfonic acid derivatives, unmodified and modified celluloses, aromatic and/or aliphatic sulfonic acids and also their adducts with formaldehyde.

[0032] Isoflucypram can be converted to customary formulations.

such as solutions, emulsions, emulsifiable concentrates, wettable powders, suspensions based on water and oil, powders, fine powders, pastes, soluble powders, soluble granules, granules for diffusion, suspoemulsion concentrates, natural products impregnated with active principle , synthetic substances impregnated with active principle, fertilizers, in addition to microencapsulations in polymeric substances.

[0033] Isoflucypram can be applied as such, in the form of its formulations or in the forms of use prepared therefrom, such as ready-to-use solutions, emulsions, suspensions based on water or oil, powders, wettable powders, pastes, soluble powders, fine powders, soluble granules, granules for diffusion, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers, in addition to microencapsulations in polymeric substances. Application is carried out in the usual manner, for example, watering, spraying, atomizing, spreading, sprinkling, foaming, spreading and the like. It is also possible to implant the active ingredients by the ultra-low volume method or to inject the preparation of the active ingredient/the active ingredient itself in the soil. It is also possible to treat the seed of plants.

[0034] The mentioned formulations can be prepared in a manner known per se, for example, by mixing the active ingredients with at least one customary extender, solvent or diluent, emulsifier, dispersant and/or binding or binding agent, wetting agent , a water repellent, driers, and UV stabilizers, if appropriate, and, if appropriate, dyes and pigments, defoamers, preservatives, secondary thickeners, adhesives, gibberellins, and other processing aids.

[0035] The present invention includes not only formulations that are ready to use and can be implanted with a suitable device in the plant or seed, but also commercial concentrates that must be diluted with water before use.

[0036] Isoflucypram may be present as such or in its (commercial) formulations and in forms of use prepared from these formulations as a mixture with other active ingredients (known), such as insecticides, attractants, sterilizers, bactericides, acaricides, nematicides , fungicides, growth regulators, herbicides, fertilizers, phytoprotectants and/or semiochemicals.

[0037] The auxiliaries used may be those substances that are suitable to impart particular properties to the composition itself or and/or to preparations derived therefrom (for example, spray liquors, seed coatings), such as certain technical properties and /or particular biological properties. Typical auxiliaries include: extenders, solvents and vehicles.

[0038] Suitable extenders are, for example, water, polar and non-polar organic chemical liquids, for example, from the classes of aromatic and non-aromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), alcohols and polyols (which can also optionally be substituted, etherified and/or esterified), ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, unsubstituted and substituted amines, amides, lactams (such as N -alkylpyrrolidones) and lactones, the sulfones and sulfoxides (such as dimethylsulfoxide).

[0039] Liquefied gaseous extenders or vehicles are understood as liquids that are gaseous at standard temperature and standard pressure, for example, aerosol propellants such as halohydrocarbons, or butane, propane, nitrogen and carbon dioxide.

[0040] In formulations, it is possible to use adhesion agents,

such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latex, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or even natural phospholipids such as cephalins and lecithins and synthetic phospholipids. Other additives can be mineral and vegetable oils.

[0041] If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents. Useful liquid solvents are essentially: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulfoxide, or still water.

[0042] Compositions containing isoflucypram may additionally contain other components, for example, surfactants. Suitable surfactants are emulsifiers and/or foamers, dispersants or wetting agents with ionic or non-ionic properties, or mixtures of these surfactants. Examples of these are polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic acid or naphthalenesulfonic acid salts, ethylene oxide polycondensates with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (preferably alkylphenols or arylphenols), ester salts sulfosuccinics, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols and derivatives of compounds containing sulphates, sulphonates and phosphates, for example alkylaryl polyglycol ethers, alkyl sulphonates, alkyl sulfates, arylsulfonates, protein hydrolysates, lignosulfite waste liquors and methylcellulose. The presence of a surfactant is necessary if one of the active ingredients and/or one of the inert vehicles is insoluble in water and when the application is carried out in water. The proportion of surfactants is between 5 and 40 percent by weight of the composition of the invention.

[0043] Other additives can be perfumes, minerals or vegetables, optionally modified oils, waxes and nutrients (including residual nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

[0044] Additional components can be stabilizers, such as cold stabilizers, preservatives, antioxidants, light stabilizers or other agents that improve chemical and/or physical stability.

[0045] If appropriate, other additional components may also be present, eg protective colloids, binders, adhesives, thickeners, thixotropic substances, penetrants, stabilizers, sequestering agents, complex-formers. In general, the active ingredients can be combined with any solid or liquid additive commonly used for formulation purposes.

[0046] The formulations generally contain between 0.05 and 99% by weight, 0.01 and 98% by weight, preferably between 0.1 and 95% by weight, more preferably between 0.5 and 90% of active ingredient most preferably between 10 and 70 percent by weight.

[0047] In one embodiment, isoflucypram formulations comprise 1 to 300 g/L of isoflucypram as an EC, SC, SE or SL formulation, preferably 10 to 250 g/L of ilsoflucypram, as an EC or SC.

[0048] The formulations described above can be used for the control of Claviceps purpurea, in which compositions containing isoflucypram are applied to cereal plants. plants

[0049] According to the invention, all plants and plant parts can be treated. By plants is meant all plants and plant populations, such as desirable and undesirable wild plants, cultivars and plant varieties (whether or not protected by plant varieties or plant breeders' rights). Cultivars and plant varieties can be plants obtained by conventional methods of propagation and improvement methods that can be assisted or supplemented by one or more biotechnological methods, such as the use of double haploids, protoplast fusion, random mutagenesis and directed, molecular or genetic markers or by bioengineering and genetic engineering methods. By plant parts we mean all parts above and below the ground and plant organs such as bud, leaf, flower and root, in which, for example, leaves, needles, stems, twigs, flowers, fruit bodies, fruits and seeds as well as roots, corms and rhizomes are listed. Crops and vegetative and generative propagation material, eg cuttings, corms, rhizomes, stolons, seedlings and seeds also belong to plant parts.

[0050] In one embodiment, the crop plants belonging to the cereal plant family are cereal plants.

[0051] In a preferred embodiment, the crop species, cultivars and varieties belonging to the cereal plants are rye, oats, barley, triticale, wheat (spring wheat or winter wheat), hybrid wheat (spring or winter wheat). winter wheat) and durum.

[0052] Most preferred plants, parts of plants or seeds according to the present invention are plants, parts of plants or seeds of wheat, plants, parts of plants or seeds of hybrid wheat; most preferred hybrid winter wheat plants, plant parts or seeds, hybrid spring wheat plants, plant parts or seeds.

[0053] In one aspect, wheat plants or plant parts are hybrid plants or plant parts. In another aspect, spring wheat plants or plant parts are hybrid spring plants or plant parts. In another aspect, winter wheat plants or plant parts are hybrid winter plants or plant parts.

[0054] The term "growth stage" refers to the growth stages defined by the BBCH codes in "Growth stages of mono- and dicotyledonous plants", 2nd edition 2001, edited by Uwe Meier of the Federal Biological Research Center for Agriculture and Forestry. BBCH codes are a well-established system for uniform coding of phonologically similar growth stages of all mono- and dicotyledonous plant species. The abbreviation BBCH derives from "Biologische Bundesanstalt, Bundessortenamt und Chemische Industrie" ("Federal Biological Institute, Federal Office of Plant Varieties and Chemical Industry).

[0055] Some of these BBCH growth stages and BBCH codes for cereal plants are given below.

[0056] Growth stage 0: Germination

[0057] 00 Dry seed (caryopsis)

[0058] 01 Start of seed soaking

[0059] 03 Complete seed soaking

[0060] 05 Radicle emerged from caryopsis

[0061] O6 Elongated radicle, visible root hairs and/or lateral roots

[0062] 07 Coleoptile emerged from caryopsis

[0063] 09 Emergency: Coleoptile penetrates the soil surface (cracking stage)

[0064] Growth stage 1: leaf 1 development

[0065] 10 First leaf through coleoptile

[0066] 11 First unfolded sheet

[0067] 12 2 unfolded sheets

[0068] 13 3 unfolded sheets

[0069] 1 Continuous stages up to. . 19 9 or more unfolded sheets

[0070] Growth stage 2: Tillering

[0071] 20 without tillers

[0072] 21 Tiller start: first detectable tiller

[0073] 22 2 detectable tillers

[0074] 23 3 detectable tillers

[0075] 2 continuous stages up to. . .29 End of profiling. Maximum number of detectable tillers

[0076] Growth stage 3: stem elongation

[0077] 30 Beginning of stem elongation: pseudostem and tillers erect, first internode begins to elongate, top of inflorescence at least 1 cm above the tillered node

[0078] 31 First knot at least 1 cm above the profiled knot

[0079] 32 Node 2 at least 2 cm above node 1

[0080] 33 Node 3 at least 2 cm above node 2

[0081] 3 - Continuous stages up to. . .37 Flag sheet barely visible, still rolled up

[0082] 39 Flag-foil stage: flag-foil completely unrolled, ligule only visible

[0083] Main growth stage 4: Rubbering 41 Initial stage of rubbering: extension of the flag leaf sheath

[0084] 43 Intermediate stage of rubbering: flag leaf sheath visibly swollen

[0085] 45 Final stage of rubbering: swollen leaf sheath - flag

[0086] 47 Opening of the flag leaf hem

[0087] 49 First visible edges (only in acuminate forms)

[0088] Main growth stage 5: Emergence of inflorescence, spike

[0089] 51 Onset of spike: tip of inflorescence emerged from sheath, first spikelet barely visible

[0090] 52 20% of the inflorescence emerged

[0091] 53 30% of the inflorescence emerged

[0092] 54 40% of the inflorescence emerged

[0093] 55 Middle of the ear: half of the inflorescence emerged

[0094] 56 60% of the inflorescence emerged

[0095] 57 70% of the inflorescence emerged

[0096] 58 80% of the inflorescence emerged

[0097] 59 End of ear: fully emerged inflorescence

[0098] Main growth stage 6: flowering, anthesis

[0099] 61 Beginning of flowering: first visible anthers

[00100] 65 Full flowering: 50% of mature anthers

[00101] 69 End of flowering: all spikelets have completed flowering, but some dehydrated anthers may remain

[00102] Main growth stage 7: Fruit development

[00103] 71 Watery grain: first grains reached half their final size 73 Initial milky

[00104] 75 Milky medium: milky grain content, grains reached final size, still green

[00105] 77 Milky end

[00106] Main growth stage 8: Ripening

[00107] 83 Initial Mass

[00108] 85 Soft mass: soft but dry grain content. Unmaintained nail print

[00109] 87 Hard mass: solid grain content. Nail print maintained

[00110] 89 Fully ripe: hard grain, difficult to share with the nail

[00111] Main growth stage 9: Senescence

[00112] 92 Very ripe: very hard grain, cannot be crushed by thumb

[00113] 93 Grains breaking out during the day

[00114] 97 Plant dead and collapsing 99 Product harvested

[00115] According to the invention, particular preference is given for the treatment of plants of plant cultivars that are commercially available or in use. Plant cultivars are understood to be plants that have new properties ("characteristics") and that were obtained by conventional crossing, mutagenesis or with the aid of recombinant DNA techniques. Crop plants can therefore be plants that can be obtained by conventional breeding and optimization methods or by biotechnology and genetic engineering methods or combinations of these methods, including transgenic plants and including plant varieties that can and cannot protected by plant variety rights.

[00116] The method according to the invention can also be used for the treatment of genetically modified organisms (GMOs), eg plants or seeds. Genetically modified plants (or transgenic plants) are plants into which a heterologous gene has been stably integrated.

to the genome. The term "heterologous gene" essentially means a gene which is supplied or assembled outside the plant and which, upon introduction into the genome of the cell nucleus, confers new or improved agronomic or other properties to the genome of the chloroplast or to the mitochondrial genome of the transformed plant by virtue of expressing a protein or polypeptide of interest or by virtue of another gene that is present in the plant, or other genes that are present in the plant, being down-regulated or silenced (for example, by means of antisense technology, co-suppression technology, or RNAi technology [RNA interference]J). A heterologous gene present in the genome is also called a transgene. A transgene that is defined by its specific presence in the plant genome is referred to as a transgenic transformation or event.

[00117] Plants and plant cultivars that are preferably treated according to the invention include all plants that possess genetic material that confers useful characteristics particularly advantageous to those plants (whether obtained by reproduction and/or biotechnological means). These plants may have been modified by mutagenesis or genetic engineering to provide a new trait to a plant or to modify an existing trait. Mutagenesis includes random mutagenesis techniques using X-rays or mutagenic chemicals, but also targeted mutagenesis techniques, to create mutations at a specific location in a plant's genome. Targeted mutagenesis techniques often use oligonucleotides or proteins such as CRISPR/Cas, zinc finger nucleases, TALENs or meganucleases to achieve the targeting effect. Genetic engineering often uses recombinant DNA techniques to create modifications in a plant's genome that, under natural circumstances, cannot easily be achieved by crossing, mutagenesis, or natural recombination. Typically, one or more genes are integrated into a plant's genome to add a trait or improve a trait. These integrated genes are also referred to as transgenes in the art, while plants comprising these transgenes are referred to as transgenic plants. The plant's transformation process usually produces several transformation events, which differ in the genomic locus where a transgene has been integrated. Plants containing a specific transgene at a specific genomic site are generally described as comprising a specific "event", which is referred to by a specific event name. Traits that have been introduced into plants or modified include herbicide tolerance, insect resistance, increased yields, and tolerance to abiotic conditions such as drought. Herbicide tolerance was created using mutagenesis as well as genetic engineering.

[00118] Plants and plant cultivars that can also be treated according to the invention are those plants that are resistant to one or more abiotic stresses. Abiotic stress conditions can include, for example, drought, exposure to cold temperature, exposure to heat, osmotic stress, flooding, increased soil salinity, increased mineral exposure, exposure to ozone, high exposure to light, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, or shade avoidance.

[00119] Plants and plant cultivars that can also be treated according to the invention are those plants characterized by increased yield. Increased yields in these plants can be the result of, for example, better plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, improved carbon assimilation , improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can further be affected by improved plant architecture (under stress and non-stress conditions), including, but not limited to, early flowering, flower control for hybrid seed production, seedling vigor. , plant size, number and distance between us, root growth, seed size, fruit size, pod size, number of pods or ears, number of seeds per pod or ear, seed mass , improved seed filling, reduced seed dispersal, reduced pod dehiscence and resistance to lodging. Other yield characteristics include seed composition such as carbohydrate content, protein content, oil content and composition, nutritional value, reduced anti-nutritional compounds, improved processing capacity, and better storage stability.

[00120] Plants that can also be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor that generally results in greater yield, vigor, health and resistance to biotic and abiotic stress factors. These plants are typically made by crossing an inbred male-sterile parent line (the female parent) with another male-fertile inbred parent line (the male parent). Hybrid seed is usually harvested from male-sterile plants and sold to growers. Male-sterile plants can sometimes (for example, in maize) be produced by dethlosing, ie mechanically removing the male reproductive organs (or male flowers), but more typically male sterility is the result of genetic determinants. in the plant genome. In that case, and especially when seed is the desired product to be harvested from the hybrid plants, it is typically helpful to ensure that male-fertility in hybrid plants that contain the genetic determinants responsible for male-sterility is fully restored. This can be done to guarantee

provided that the male parents have adequate fertility restorer genes that are capable of restoring male fertility in hybrid plants that contain the genetic determinants responsible for male sterility. Genetic determinants of male sterility may be located in the cytoplasm. Examples of cytoplasmic male sterility (CMS) have, for example, been described in Brassica species (WO 1992/005251, WO 1995/009910, WO 1998/27806, WO 2005/002324, WO 2006 /021972 and US 6,229,072). However, genetic determinants of male sterility can also be located in the nuclear genome. Male-sterile plants can also be obtained by plant biotechnology methods such as genetic engineering. A particularly useful means of obtaining male-sterile plants is described in WO 89/10396, in which, for example, a ribonuclease such as barnase is selectively expressed in tapetal cells in the stamens. Fertility can then be restored by expression in tapetum cells of a ribonuclease inhibitor such as barstar (eg WO 1991/002069).

[00121] Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated in accordance with the invention are herbicide tolerant plants, i.e. plants made tolerant to one or more given herbicides . These plants can be obtained by genetic transformation or by selection of plants containing a mutation that confers such herbicide tolerance. Herbicide tolerance was created through the use of transgenes for glyphosate, glufosinate, 2,4-D, dicamba, oxynyl herbicides such as bromoxynil and ioxynil, sulfonylurea herbicides, ALS inhibitors, and 4-hydroxyphenylpyruvate dioxygenase inhibitors (HPPD) such as isoxaflutol and mesotrione. Transgenes that have been used to provide comprehensive herbicide tolerance traits.

dem: for glyphosate tolerance: cp4 epsps, epsps grg23ace5, mepsps, 2mepsps, gat4601, gat4621, goxv247; for glufosinate tolerance: pat and bar, for 2,4-D tolerance: aad-1, aad-12; for dicamba tolerance: dmo; for tolerance to oxynyl herbicides: bxn; for tolerance to sulfonylurea herbicides: zm-hra, csr1-2, gm-hra, S4-HrA; for tolerance to ALS inhibitors: csr1-2; and for tolerance to HPPD inhibitors: hppdPF, W336, avhppd-03.

Herbicide tolerant plants are, for example, glyphosate tolerant plants, i.e. plants made tolerant to the herbicide glyphosate or its salts. For example, glyphosate tolerant plants can be obtained by transforming the plant with a gene that encodes the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS). Examples of these EPSPS genes are the AroA gene (CT7 mutant) of the bacterium Salmonella typhimurium (Comai et al., Science (1983), 221, 370-371), the CP4 gene of the bacterium Agrobacterium sp. (Barry et al., Curr. Topics Plant Physiol. (1992), 7, 139-145), the genes encoding an EPSPS petunia (Shah et al., Science (1986), 233, 478-481), a tomato EPSPS (Gasser et al., J. Biol. Chem. (1988), 263, 4280-4289) or Eleusine EPSPS (WO 2001/66704). It can also be a mutated EPSPS, as described, for example, in EP-A 0837944, WO 2000/066746, WO 2000/066747 or WO 2002/026995. Glyphosate tolerant plants can also be obtained by expressing a gene encoding a glyphosate oxidoreductase enzyme, as described in US 776 760 and US 5 463 175. Glyphosate tolerant plants can also be obtained by expressing a gene encoding a glyphosate ace- Useful transferase as described, for example, in WO 2002/036782 , WO 2003/092360 , WO 2005/012515 and WO 2007/024782 . Glyphosate tolerant plants can also be obtained by selecting plants containing naturally occurring mutations of the above mentioned genes, as described, for example, in WO 2001/024615 or WO 2003/013226.

[00123] Other herbicide-resistant plants are, for example, plants that have become tolerant to herbicides by inhibiting the glutamine synthase enzyme, such as bialaphos, phosphinothricin or glufosinate. These plants can be obtained expressing an enzyme that detoxifies the herbicide or a mutant glutamine synthase enzyme that is resistant to inhibition. One of these efficient detoxifying enzymes is, for example, an enzyme that encodes a phosphinothricin acetyltransferase (such as the bar or pat protein of the Streptomyces species). Plants expressing an exogenous phosphinothricin acetyltransferase are, for example, described in US 5,561,236; US 5,648,477; US 5,646,024; US 5,273,894; US 5,637,489; US 5 276 268; US 5,739,082; US 5908810 and US 7,112,665.

[00124] Other herbicide tolerant plants are also plants that have become tolerant to herbicides by inhibiting the enzyme hydroxyphenylpyruvatodioxygenase (hydroxyphenylpyruvatedioxygenase - HPPD). Hydroxyphenylpyruvatedioxygenases are enzymes that catalyze the reaction in which para-hydroxyphenylpyruvate (para-hydroxyphenylpyruvate HPP) is transformed into homogentisate. Plants tolerant to HPPD inhibitors can be transformed with a gene encoding a naturally occurring resistant HPPD enzyme, or a gene encoding a mutated HPPD enzyme according to WO 1996/038567, WO 1999/024585 and WO 1999/024586 . Tolerance to HPPD inhibitors can also be achieved by transforming plants with genes that encode certain enzymes that allow for the formation of homogentisate, despite the inhibition of the native HPPD enzyme by the HPPD inhibitor. Such plants and genes are described in WO 1999/034008 and WO 2002/36787. Tolerance of plants to HPPD inhibitors can also be improved by transforming plants with a gene encoding a prephenate dehydrogenase enzyme in addition to a gene encoding an HPPD tolerant enzyme, as described in WO

2004/024928.

[00125] Other herbicide resistant plants are plants that have become tolerant to acetolactate synthase inhibitors (acetolactate synthase - ALS). Known ALS inhibitors include, for example, sulfonylurea, imidazolinone, triazolopyrimidines, pyrimidinyloxy(thio)benzoates and/or sulfonylaminocarbonyltriazolinone herbicides. Different mutations in the ALS enzyme (also known as acetohydroxy acid synthase, AHAS) are known to confer tolerance to different herbicides and herbicide groups, as described for example in Tranel and Wright, Weed Science (Weed Science) (2002) ), 50, 700-712, but also in US 5,605,011, US 5,378,824, US

5,141,870 and US 5,013,659. The production of sulfonylurea tolerant plants and imidazolinone tolerant plants is described in US

5,605,011; US 5,013,659; US 5,141,870; US 5,767,361; US 5,731,180; US 5,304,732; US 4,761,373; US 5,331,107; US 5,928,937; and us

5,378,824; and international publication WO 1996/033270. Other imidazolinone tolerant plants are also described in, for example, WO 2004/040012, WO 2004/106529, WO 2005/020673, WO 2005/093093, WO 2006/007373, WO 2006/015376, WO 2006/024351 and WO 2006/060634. Other sulfonylurea and imidazolinone tolerant plants are also described in, for example, WO 2007/024782.

[00126] Other imidazolinone and/or sulfonylurea tolerant plants can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or by mutation reproduction as described, for example, for soybeans in US 5,084,082, for rice in WO 1997/41218 for sugar beet in US 5,773,702 and WO 1999/057965 for lettuce in US 5,198,599 or for sunflower in WO 2001/065922.

[00127] Events from transgenic corn containing herbicide tolerance genes include, but are not limited to, DAS40278, MON801,

MON802, MON809, MON810, MON832, MON87411, MONB87419, MONB87427, MON88017, MON89034, NK603, GA21, MZHGOJG, HCEMA485, - VCO-01981 5, 676, 678, 680, 33121, 41 14, 59122, 98140 , CBH-351, DBT418, DLL25, MS3, MS6, MZIRO98, T25, TC1507 and TC6275. Transgenic soybean events containing herbicide tolerance genes include, but are not limited to, GTS 40-3-2, MON87705, MON87708, MON87712, MON87769, MON89788, A2704-12, A2704-21, A5SS47-127, A5SS47-35 , DP356043, DAS44406-6, DASG68416-4, DAS-81419-2, GU262, SYHTOH2, W62, W98, FG72 and CV127. Transgenic cotton events containing herbicide tolerance genes include, but are not limited to, 19-51 a, 31707, 42317, 81910, 281 -24-236, 3006-210-23, BXN1021 1, BXN10215, BXN10222, BXN10224, MON1445, MON 1698 MONB88701, MONB88913, GHB1 19, GHB614, LLCotton25, T303-3 and T304-40. Transgenic canola events containing herbicide tolerance genes are, for example, but not excluding others, MON88302, HCR-1, HOCN10, HCN28, HCN92, MS1, MS8, PHY14, PHY23, PHY35, PHY36, RF1, RF2 and RF3.

[00128] Insect resistance was created mainly by the transfer of bacterial genes encoding insecticidal proteins to plants: Transgenes that have been used most frequently are Bacillus spp toxin genes. and its synthetic variants, Cry1A, crylAb, cry1Ab-Ac, crylAc, cry1A.105, cry1l F, cry1l Fa2, cry2Ab2, cry2e, mcery3A, ecry3.1Ab, cry3Bb1 , cry34Ab1 , cry35Ab1 , cryA3(a. However, also genes of plant origin, such as genes that encode protease inhibitors, such as CpTI and pin 11, were transferred to other plants. Another approach uses transgenes like dvsnf7 to produce double-stranded RNA in plants.

[00129] Transgenic corn events containing genes encoding insecticidal proteins or double-stranded RNA include, but are not limited to, Bt10, Bt11, Bt176, MON801, MON802, MON809, MONB810, MON863, MON8741 1, MON88017, MON89034 , 33121, 4114, 5307, 59122, TC1507, TO6275, CBH-351, MIR162, DBT418 and MZIRO98. Events from transgenic soy containing genes for insecticidal proteins include, but are not limited to, MON87701, MON87751 and DAS-

81419. Events from transgenic cotton containing genes for insecticidal proteins include, but are not limited to, SGK321, MON531, MON757, MON1076, MON15985, 31707, 31803, 31807, 31808, 42317, BNLA-601, Eventl, COT67B, COT102 , T303-3, T304-40, GFM Cry1A, GK12, MLS 9124, 281-24-236, 3006-210-23, GHB1 19 and SGK321.

[00130] Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can also be treated according to the invention are tolerant to abiotic stress factors. These plants can be obtained by genetic transformation or by selection of plants containing a mutation that confers resistance to stress. Particularly useful stress-tolerant plants include:

a) plants that contain a transgene capable of reducing the expression and/or activity of the poly (ADP-ribose) polymerase (PARP) gene in plant cells or plants as described in WO 2000/004173 or EP 04077984.5 or EP 06009836.5;

[00132] Db) plants that contain a stress-tolerance-increasing transgene capable of reducing the expression and/or activity of genes encoding PARG in plants or plant cells as described, for example, in WO 2004/ 090140;

[00133] c) plants containing a stress tolerance enhancing transgene encoding a functional plant enzyme of the adenine nicotinamide dinucleotide recovery biosynthesis pathway,

including nicotinamidase, nicotinate phosphoribosyltransferase, nicotinic acid mononucleotide adenyltransferase, nicotinamide adenine dinucleotide synthetase or nicotinamide phosphoribosyltransferase as described, for example, in EP 04077624.7 or WO 2006/133827/002433/EP07.

[00134] Plants that possess singular or stacked characteristics, as well as the genes and events that provide these characteristics, are well known in the art. For example, detailed information about mutagenized or integrated genes and related events is available on the websites of the organizations "International Service for the Acquisition of Agri-biotech Applications (ISAAA)". Biotechnology) and "Center for Environmental Risk Assessment (CERA)" (Center for Environmental Risk Assessment).

[00135] The foliar treatment of plants has been known for a long time and is in constant improvement. However, the treatment of plants gives rise to a series of problems that cannot always be resolved satisfactorily. For example, it is desirable to develop methods to protect the plant, the developing inflorescence and the seed. It is additionally desirable to optimize the amount of Isoflucypram used in order to provide the best possible protection for the plant, in particular for the developing inflorescence from attack by Claviceps purpurea, but without damaging the cereal plant itself by the active ingredient used.

[00136] In another embodiment, a method of treating plants to control Claviceps purpurea in BBCH stage 50 or later cereal plants by treating the BBCH 50 stage cereal plant with Isoflucypram.

[00137] In another embodiment, a method to treat plants to control Claviceps purpurea in cereal plants between BBCH stage 50 and 80 is treating the BBCH stage 50 cereal plant with Isoflucypram.

[00138] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in cereal plants at BBCH stage 90 or later by treating the BBCH 50 stage cereal plant with Isoflucypram.

[00139] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in cereal plants at BBCH stage 90 or later, treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

[00140] In another embodiment, a method of treating plants to control Claviceps purpurea in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants at BBCH stage 50 or later treating the BBCH 50 cereal plant with Isoflucypram.

[00141] In another embodiment, a method to treat plants to control Claviceps purpurea in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants between BBCH stage 50 and 80 treating the BBCH 50 cereal plant with Isoflucypram.

[00142] In another embodiment, a method of treating plants to reduce Claviceps purpurea sclerotia in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants at BBCH stage 90 or later, treating the BBCH 50 stage cereal plant with Isoflucypram.

[00143] In another embodiment, a method of treating plants to reduce Claviceps purpurea sclerotia in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants at BBCH 90 or post-

later, treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

[00144] In another embodiment, a method to treat plants to control Claviceps purpurea in BBCH stage 50 or later spring wheat plants by treating the BBCH 50 stage cereal plant with Isoflucypram.

[00145] In another embodiment, a method to treat plants to control Claviceps purpurea in spring wheat plants between BBCH stage 50 and 80, treating the BBCH stage 50 cereal plant with Isoflucypram.

[00146] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in BBCH stage 90 or later spring wheat plants by treating the BBCH 50 stage cereal plant with Isoflucypram.

[00147] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in spring wheat plants at BBCH stage 90 or later, treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

[00148] In another embodiment, a method to treat plants to control Claviceps purpurea in hybrid spring wheat plants at BBCH stage 50 or later by treating the BBCH stage 50 cereal plant with Isoflucypram.

[00149] In another embodiment, a method to treat plants to control Claviceps purpurea in hybrid spring wheat plants between BBCH stage 50 and 80, treating the BBCH stage 50 cereal plant with Isoflucypram.

[00150] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in hybrid spring wheat plants at BBCH stage 90 or later by treating the BBCH stage 50 cereal plant with Isoflucypram.

[00151] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in hybrid spring wheat plants at BBCH stage 90 or later, treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

[00152] In another embodiment, a method to treat plants to control Claviceps purpurea in BBCH stage 50 or later winter wheat plants by treating the BBCH 50 stage cereal plant with Isoflucypram.

[00153] In another embodiment, a method to treat plants to control Claviceps purpurea in winter wheat plants between BBCH stage 50 and 80, treating the BBCH stage 50 cereal plant with Isoflucypram.

[00154] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in BBCH stage 90 or later winter wheat plants by treating the BBCH 50 stage cereal plant with Isoflucypram.

[00155] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in winter wheat plants at BBCH stage 90 or later, treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

[00156] In another embodiment, a method to treat plants to control Claviceps purpurea in hybrid winter wheat plants at BBCH stage 50 or later by treating the BBCH stage 50 cereal plant with Isoflucypram.

[00157] In another embodiment, a method to treat plants to control Claviceps purpurea in hybrid winter wheat plants between BBCH stage 50 and 80, treating the BBCH stage 50 cereal plant with Isoflucypram.

[00158] In another embodiment, a method of treating plants to reduce Claviceps purpurea sclerotia in wheat plants from in.

verno hybrids at BBCH stage 90 or later, treating cereal plant at BBCH 50 with Isoflucypram.

[00159] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in hybrid winter wheat plants at BBCH stage 90 or later, treating the cereal plant between BBCH stages 50 and 80 with Isoflucypram.

[00160] In another embodiment, a method of treating plants to control Claviceps purpurea in barley, rye, triticale or durum plants at BBCH stage 50 or later by treating the BBCH stage 50 cereal plant with Isoflucypram.

[00161] In another embodiment, a method of treating plants to control Claviceps purpurea in barley, rye, triticale or durum plants between BBCH stage 50 and 80 is treating the BBCH stage 50 cereal plant with Isoflucypram.

[00162] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in barley, rye, triticale or durum plants at BBCH stage 90 or later by treating the BBCH stage 50 cereal plant with Isoflucypram.

[00163] In another embodiment, a method to treat plants to reduce Claviceps purpurea sclerotia in barley, rye, triticale or durum plants at BBCH stage 90 or later, treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

[00164] One of the advantages of the present invention is that, due to the particular systemic properties of isoflucypram, the treatment of the cereal plant during flowering with isoflucypram, allows not only the control of Claviceps purpurea in the plant itself, but also in the seeds in development resulting in a reduction of sclerotia in the harvested grain. mixtures

[00165] —Isoflucypram can be mixed with other active ingredients such as fungicides, bactericides, acaricides, nematicides, insecticides, herbicides, fertilizers, growth regulators, plant protection agents or semiochemicals. This can allow you to broaden the spectrum of activities or prevent the development of resistance. Examples of known fungicides, insecticides, acaricides, nematicides, and bactericides are disclosed in the Pesticide Manual, 17th Edition.

[00166] "When a compound (A) or a compound (B) may be present in tautomeric form, that compound is understood herein above and hereinafter to also include, where applicable, the corresponding tautomeric forms, even when these are not specified. mentioned in each case.

[00167] All named mixing partners may, if their functional groups permit, optionally form salts with suitable bases or acids.

[00168] Examples of especially preferred fungicides that can be mixed with isoflucypram are:

[00169] 1) ergosterol biosynthesis inhibitors, for example (1,001) cyproconazole, (1,002) difenoconazole, (1,003) epoxiconazole, (1,004) fenexamide, (1,05) fenpropidine, (1,006) fenpropimorph, (1,007) fenpyrazamine, (1,008 ) fluquinconazole, (1,009) flutriafol, (1,010) imazalil, (1,011) imazalyl sulfate, (1,012) ipconazol, (1,013) metconazol|, (1,014) myclobutanil, (1,015) paclobutrazol, (1,016) prochloraz, (1,017) propiconazole, (1,018) prothioconazole, (1,019) pyrisoxazole, (1,020) spiroxamine, (1,021) tebuconazole, (1,022) tetraconazole, (1,023) triadimenol, (1,024) tridemorph, (1,025) triticonazol, (1,026) (1R,2S, 5S)-5-(4-chloro-benzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentane]|, (1,027) (18, 2R,5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)-cyclopentanol, = (1,028) (2R) -2-(1-chlorocyclopropyl)-4-[[1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-01, — (1,029)

(2R)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol , (1,030) (2R)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1,031) (2S)-2-(1-chlorocyclopropyl)-4-[(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan- 2-ol, (1,032) (2S)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl) butan-2-01l, (1,033) (2S8)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl )propan-2-01, (1,034) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin- 3-yl)methanol, (1,035) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-0xazol-4-yl](pyridin -3-yl) methanol, (1,036) [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3- il) methanol, (1,037) 1-(1((2R,48S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylkmethyl)- 1H-1,2,4-triazole, (1,038) 1-(((28.4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxo- there an-2-ilymethyl)-1H-1,2,4-triazole, (1,039) 1-([3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl thiocyanate )-1H-1,2,4-triazol-5-yl, (1,040) 14[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran thiocyanate -2-yl]methyl)-1H-1,2,4-triazol-5S-yl, (1,041) 1-([rel(2R,3S)-3-(2-chlorophenyl)-2-(2 ,4-difluorophenyl)oxiran-2-yl]methyl)-1H-1,2,4-triazol-S-yl, (1042) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl )-5-hydroxy-2,6,6-trimethyl-heptan-4-yl1]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,043) 2-[( 2R,4R,58)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2, 4-Triazol-3-thione, (1,044) 2-[(2R,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy -2,6,6-trimethyl-heptan-4-yl] -2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,045) 2-[(2R,48.58)-1-(2,4-dichlorophenyl)-5-hydroxy -2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,046) 2-[(28.4R,5R )-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole - 3-thione, (1,047) 2- [(28.4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-11]-2,4-dihydro-3H- 1,2,4-triazol-3-thione, (1,048) 2-[(2S,AS, 5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan- 4-yl]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,049) 2-[(28.4S,58)-1-(2,4-dichlorophenyl) -5-

hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,050) 2-[1-(2, 4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,051) 2 -[2-chloro-4-(2,4-dichlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1,052) 2-[2-chloro -4-(4-chlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-01l, (1,053) 2-[4-(4-chlorophenoxy] )-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1,054) 2-[4-(4-chlorophenoxy)-2-( trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)pentan-2-01, (1,055) mefentrifluconazole, (1,056) 24[3-(2-chlorophenyl)-2-(2 ,4-difluorophenyl)oxiran-2-yl]methyl)-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,057) 2-f[rel(2R,3R)- 3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl)-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,058 ) 2-([rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl)-2,4-dihydro-3H-1, 2,4-triazol-3-thione, — (1,059) 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylme ethyl)cyclopentanol, (1,060) 5-(allylsulfanyl)-1-f[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl)-1H-1,2 ,4-triazole, (1,061) 5-(allylsulfanyl)-1-f[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-ylmethyl)-1H -1,2,4-triazole, (1,062) 5-(allylsulfanyl)-1-f[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran- 2-yl]methyl)-1H-1,2,4-triazole, (1,063) N-(2,5-dimethyl-4-([3-(1,1,2,2-tetrafluoroethoxy)phenyl]sulfanyl) enyl)-N-ethyl-N-methylimidoformamide, (1,064) N'-(2,5-dimethyl-4-([3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl)enyl)-N-ethyl- N-methylimidoformamide, (1,065) N'-(2,5-dimethyl-4-([3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl)phenyl)-N-ethyl-N-methylimidoformamide , (1,066) N'-(2,5-dimethyl-4-([[3-(pentafluoroethoxy)phenyl]sulfanyl)phenyl)-N-ethyl-N-methylimidoformamide, (1,067) N'-(2,5- dimethyl-4-(3-[(1,1,2,2-tetrafluoroethyl)sulfanyl/phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (1,068) — N'-(2,5-dimethyl-4-(3-[ (2,2,2-trifluoroethyl)|sulfanyl]phenoxyphenyl)-N-ethyl-N-methylimidoformami da, (1,069) N'-(2,5-dimethyl-4-(3-[(2,2,3,3-tetrafluoropropyl)sulfanyl-phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (1,070) N' -(2,5-dimethyl-4-(3-[(pentafluoroethyl)sulfanyl]phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (1,071) N'-(2,5-dimethyl-4-phenoxyphenyl)- N-ethyl-N-methylimi-

doformamide, (1,072) N'-(4-([3-(difluoromethoxy)phenyl]sulfanyl)-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1,073) N'-(4-( 3-[(difluoromethyl)sulfanyl]phenoxy)-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, — (1,074) N'-[5-bromo-6-(2,3-dihydro-1H) -inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylimidoformamide, (1,075) N'-(4-[(4,5-dichloro-1,3-thiazol-2- yl)Oxy]-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1,076) N'-(5-bromo-6-[(1R)-1-(3,5-difluorophenyl)ethoxy]- 2-methylpyridin-3-yl)-N-ethyl-N-methylimidoformamide, (1,077) N'(5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy] 1-2 -methyl-pyridin-3-yl)-N-ethyl-N-methylimidoformamide, (1,078) N'-(5-bromo-6-[(cis-4-isopropyylcyclohexyl)oxy]-2-methylpyridin-3- yl)-N-ethyl-N-methylimidoformamide, (1,079) N'-(5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl)- N-ethyl-N-methylimidoformamide, (1,080) N'-(5-bromo-6-[1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl)-N-ethyl-N-methylimidoformamide , (1081) ipfentrifluconazole, and (1082) 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol.]

[00170] 2) complex respiratory chain inhibitors | or II, for example (2001) benzovindiflupyr, (2002) bixafen, (2003) boscalide, (2000) carboxin, (2000) fluopyram, (2006) flutolanil, (2007) fluxapyroxidade, (2008) furametpyr (2009) Isofetamide, (2010) isopyrazam (1R,48.9S anti-epimeric enantiomer), (2,011) isopyrazam (1S8,4R,9R anti-epimeric enantiomer), (2012) isopyrazam (1RS,4SR,9SR anti-epimeric racemate ), (2013) isopyrazam (mixture of epimeric syn-racemate 1IRS,4SR,9RS and epimeric anti-racemate 1RS,4SR,9SR), (2014) isopyrazam (1R,4S,9R epimeric syn-enantiomer), (2015) iso - pirazam (1S8.4R,9S epimeric syn-enantiomer), (2016) isopirazam (1IRS,4SR,9RS epimeric syn-racemate), (2017) penflufem, (2018) penthiopyrad, (2019) pidiflumetofem, (2020) piraziflumide, (2021) sedaxane, (2022) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazol-4- carboxamide, (2023) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide , (2024) 1,3-dime-

Tyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazol-4-carboxamide, (2025) 1-methyl -3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (2026) 2-fluoro-6-(trifluoromethyl)-N-(1,1 ,3-trimethyl-2,3-dihydro-1H-inden-4-yl)benzamide, (2027) 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3 -dihydro-1H-inden-4-yl)-1H-pyrazol-4-carboxamide, (2028) 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3- trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2029) 3-(difluoromethyl)-1-methyl-N-[(3S)-1 ,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2030) 3-(difluoromethyl)-N-(7-fluoro-1, 1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, (2,031) 3-(difluoromethyl)-N-[( 3R)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide, — (2,032) 3- (difluoromethyl)-N-[(3S)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazol-4-yl carboxamide, (2033) 5,8-difluoro-N-[2-( 2-fluoro-4-([4-(trifluoromethyl)pyridin-2-yloxyXphenyl)ethyl|quinazolin-4-amine, (2034) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3-(difluoromethyl )-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2,035) N-(2-t-butyl-5-methylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro -1-methyl-1H-pyrazole-4-carboxamide, (2036) N-(2-t-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide , (2037) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2038) N-( 5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazol-4-carboxamide, — (2039) N-[(1R,4S)- 9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanephthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2040) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H- pyrazole-4-carboxamide, (2041) N-[1-(2,4-dichlorophenyl)-I-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl- 1H-pyrazole-4-carboxamide, (2,042) N-[2-chloro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazol-4- carboxamide, — (2043) N-[3-chloro-2-fluoro-6-(trifluoromethyl)

benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2044) N-[5-chloro-2-(trifluoromethyl)benzyl]-N- cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2,045) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[5- methyl-2-(trifluoromethyl)benzyl]-1H-pyrazole-4-carboxamide, (2046) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-fluoro-6-isopropylbenzyl)-1-methyl -1H-pyrazole-4-carboxamide, (2047) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-5-methylbenzyl)-1-methyl-1H-pyrazole- 4-carboxamide, — (2048) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazol-4-carbothioamide, (2049) N-cyclopropyl -3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-benzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2,050) N-cyclopropyl-3-(difluoromethyl)-5- fluoro-N-(5-fluoro-2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2051) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-4,5- dimethylbenzyl)-5-fluoro-1-methyl-1H-pyrazol-4-car boxamide, (2052) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2,053) N- cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-methyl-benzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2,054) N-cyclopropyl-N-(2- cyclopropyl-5-fluorobenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2,055) N-cyclopropyl-N-(2-cyclopropyl-5-methyl-benzyl)- 3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2,056) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3-(difluoromethyl)-5-fluoro-1- methyl-1H-pyrazole-4-carboxamide; (2057) pyrapropoin

3) respiratory chain inhibitors in complex III, for example (3001) amethoctradine, (3002) amisulbrom, (3003) azoxystrobin, (3004) cumethoxystrobin, (3005) cumoxystrobin, (3006) cyazophamide, (300) 3,007) dimoxystrobin, (3,008) enoxastrobin, (3,009) famoxadone, (3,010) fenamidone, (3,011) fluphenoxystrobin, (3,012) fluoxastrobin, (3,013) kresoxim-methyl, (3,014) metominostrobin, (3,015) orisastrobin, (3,016) picoxystrobin, (3,017) pyraclostrobin, (3,018) pyramethostrobin, (3,019) pyraoxystrobin, (3,020) trifloxystrobin,

(3,021) (2E)-2-(2-[([(1E)-1-(34[(E)-1-fluoro-2-phenylvinyl]oxyXphenyl)ethylidene]aminoJoxy)methyl]phenyl)-2-(methoxyimino) -N-methylacetamide, (3,022) (2E, 32Z)-5-([1-(4-chlorophenyl)-1H-pyrazol-3-yloxy)-2-(methoxyimino)-N,3-dimethyl-pent-3 -enamide, — (3,023) (2R)-2-(2-[(2,5-dimethylphenoxy)methyl]phenyl)-2-methoxy-N-methylacetamide, (3,024) (28S)-2-(2-[ (2,5-dimethylphenoxy): methylphenyl)-2-methoxy-N-methylacetamide, (3,025) fenpicoxamide, (3,026) mandestrobin, (3,027) N-(3-ethyl-3,5,5-trimethylcyclohexyl )-3-formamido-2-hydroxybenzamide, (3,028) (2E,32Z)-5-([1-(4-chloro-2-fluorophenyl)-1H-pyrazol-3-yloxy)-2-(methoxyimino )-N,3-dimethylpent-3-enamide, (3,029) methyl (5-[3-(2 4-dimethylphenyl)-1H-pyrazol-1-yl]-2-methylbenzyl)carbamate, (3,030) methyltetraprol , (3,031) florilpicoxamide.

4) inhibitors of mitosis and cell division, for example (4,001) carbendazim, (4,002) diethencarb, (4,003) ethaboxam, (4,004) fluopicolide, (4,005) pencycuron, (4,006) thiabendazol, (4,007) thiophanate-methyl , (4,008) zoxamide, (4,009) 3-chloro-4-(2,6-difluorophenyl)-6-methyl-B5-phenylpyridazine, (4.010) 3-chloro-5-(4-chlorophenyl)-4-(2 ,6-difluorophenyl)-6-methylpyridazine, (4,011) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine, (4,012) 4 -(2-bromo-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4,013) 4-(2-bromo-4-fluoro - phenyl)-N-(2-bromo-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4,014) 4-(2-bromo-4-fluorophenyl)-N-(2- bromophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.015) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl- 1H-pyrazol-5-amine, (4.016) 4-(2-bromo-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4,017) 4-(2-bromo-4-fluoro-phenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, = (4.0 18) 4-(2-chloro-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.019) 4-(2-chloro-4- fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4,020) 4-(2-chloro-4-fluorophenyl)-N-(2-chlorophenyl) )-1,3-dimethyl-1H-pyrazol-5-amine, (4,021) 4-(2-chloro-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazole -5-amine, (4,022) 4-(4-chlorophenyl)-5-(2,6-

difluorophenyl)-3,6-dimethylpyridazine, (4,023) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4,024) N-(2-bromophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4,025) N-(4-chloro-2 ,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine;

[00173] 5) compounds capable of having a multisite action, for example (5.001) burgundy mixture, (5.002)captafol, (5.003)captan, (5.004) chlorothalonil, (5.005) copper hydroxide, (5.006) naphthenate copper, (5,007) copper oxide, (5,008) copper oxychloride, (5,009) copper sulfate (2+), (5.010) dithianone, (5,011) dodine, (5,012) folpet, (5,013) mancozeb, (5,014 ) maneb, (5,015) putir, (5,016) put zinc, (5,017) oxine-copper, (5,018) propineb, (5,019) sulfur and sulfur preparations, including calcium polysulfide, (5,020) removed, (5,021) zineb, (5,022) ziram and (5,023) 6-ethyl-5,7-dioxo-6,7-dihydro-5H-pyrrolo[3',4':5,6][14]dithiino[2, 3-c][1,2]thiazol-3-carbonitrile;

6) compounds capable of inducing a host defense, for example (6001) acibenzolar-S-methyl, (6002) isotianil, (6.003) probenazol, (6.004) tiadinil;

7) inhibitors of amino acid and/or protein biosynthesis, for example (7001) cyprodinil, (7,002) kasugamycin, (7,003) kasugamycin hydrochloride hydrate, (7,004) oxytetracycline, (7,005) pyrimethanil, (7,006 ) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline.

[00176] 8) inhibitors of ATP production e.g. (8001) silti-ofam;

[00177] 9) cell wall synthesis inhibitors, for example (9.001) bentiavalcarb, (9.002) dimethomorph, (9.003) flumorph, (9.004) iprovalicarb, (9.005) mandipropamide, (9.006) pyrimorph, (9.007) valifenalate , (9.008) (2E)-3-(4-t-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, ( 9,009) (22Z)-3-(4-t-butylphenyl)-3-(2-chloropyridin-4-yl)-

1-(morpholin-4-yl)prop-2-en-1-one;

10) lipid and membrane synthesis inhibitors, for example (10.001) propamocarb, (10.002) propamocarb hydrochloride, (10.003) tolclophos-methyl;

[00179] 11) melanin biosynthesis inhibitors, for example (11,001) tricyclazole, (11,002) 2,2,2-trifluoroethyl(3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl)carbamate ;

12) nucleic acid synthesis inhibitors, for example (12,001) benalaxyl, (12,002) benalaxyl-M (chiralaxyl), (12,003) metalaxyl and (12,004) metalaxyl-M (mefenoxam);

13) signal transduction inhibitors, for example (13,001) fludioxonil, (13,002) iprodione, (13,003) procymidone, (13,004) proquinazide, (13,005) quinoxifene, (13,006) vinclozoline;

[00182] 14) compounds capable of acting as uncouplers, for example (14,001) fluazinam, (14,002) meptyldynocape;

[00183] 15) Other compounds, for example (15,001) abscisic acid, (15,002) bentiazol, (15,003) betoxazine, (15,004) capsimycin, (15,05) carvone, (15,006) quinomethionate, (15,007) cufraneb, (15,008 ) cyflufenamide, (15,009) cymoxanil, (15,010) cyprosulfamide, (15,011) flutianil, (15,012) fosetyl aluminum, (15,013) fosetyl calcium, (15,014) fosetyl sodium, (15,015) methyl isothiocyanate, (15,016) metra - phenone, (15,017) mildiomycin, (15,018) natamycin, (15,019) nickel dimethyldithiocarbamate, (15.020) nitrothal-isopropyl, (15,021) oxamocarb, (15,022) oxathiapiproline, (15,023) oxyphenthin, (15,024) pentaclo - rophenol and salts, (15,025) phosphorous acid and its salts, (15,026) propamocarbphosetylate, (15,027) pyriophenone (clazafenone), (15,028) tebufloquine, (15,029) teclophthalam, (15,030) tolniphanide, (15,031) ) 1-(4-(4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-0xazol-3-yl]-1,3-thiazol-2 -yl)piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylJethanone, (15,032) 1-(4-14-[(58)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-0xazol-3-yl]-1,3-thiazol-2-yl )

piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylJethanone, (15,033) 2-(6-benzylpyridin-2-yl)quinazoline, (15,034) dipimethitrone, (15,035) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-(5-[2-(prop-2-yn-1-yloxy)phenyl ]-4,5-dihydro-1,2-Oxazol-3-yl)-1,3-thiazol-2-yl)piperidin-1-ylethanone, (15,036) 2-[3,5-bis(difluoromethyl) )-1H-pyrazol-1-yl]-1-[4-(4-(5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro -1,2-Oxazol-3-yl)-1,3-thiazol-2-yl)piperidin-1-ylJetanone, (15,037) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl ]-1-[4-(4-(5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3- yl)-1,3-thiazol-2-yl)piperidin-1-ylJethanone, (15,038) 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2-yl]|quinazoline, (15,039 ) 24(5R)-3-[2-(1-1[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazol-4-yl] -4,5-dihydro-1,2-0xazol-5-yl)-3-chlorophenyl methanesulfonate, (15.040) 2-1(58)-3-[2-(1-([3,5-bis) (difluoromethyl)-1H-pyrazol-1-yl]acetyl)piperidin-4-yl)-1,3-thiazol-4-yl ]-4,5-dihydro-1,2-Oxazol-5-yl)-3-chlorophenyl methanesulfonate, (15,041) ipflufenoquine, (15,042) 2-(2-fluoro-6-[(8-fluoro) -2-methyl-quinolin-3-yl)oxyphenyl)propan-2-ol, (15,043) fluoxapiproline, (15,044) 2-13-[2-(14[3,5-bis(difluoromethyl)-1H-pyrazole -1-yl]acetyl)piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-ylYenyl methanesulfonate, (15,045) 2-phenylphenol and salts , (15,046) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (15,047) quinofumeline, (15,048) 4-amino-5 - fluoropyrimidin-2-01 (tautomeric form: 4-amino-5-fluoropyrimidin-2(1H)-one), (15,049) 4-0x0-4-[(2-phenylethyl)amino]butanoic acid, (15,050) 5 -amino-1,3,4-thiadiazol-2-thiol, (15,051) S5-chloro-N'-phenyl-N'-(prop-2-yn-1-yl)thiophene-2-sulfone-hydrazide, ( 15,052) 5-fluoro-2-[(4-fluorobenzyl)oxylpyrimidin-4-amine, (15,053) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine, (15,054) 9- fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1,4-benzoxazepine, (15,055) but-3-yn-1-ylf6-[(f[( Z)-(1-met yl-1H-tetrazol-5-yl)(phenyl)methylene]amino)oxy)methyl]pyridin-2-yl)carbamate, (15,056) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (15,057 ) phenazine-1-carboxylic acid, (15,058) propyl 3,4,5-tri-hydroxybenzoate,

(15,059) quinolin-8-ol, (15,060) quinolin-8-ol sulfate (2:1), (15,061) (6-[(I(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene t-butyl]amino)oxy)methyl]pyridin-2-yl)carbamate, (15,062) 5-fluoro-4-imino-3-methyl-1-[(4-methylphenyl)sulfonyl]-3,4-di -hydropyrimidin-2(1H)-one, (15,063) aminopyrifene, (15,064) — (N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylimidoformamide ) (15,065) (N'-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methyllimidoformamide), (15,066) (2-(2-[(7,8-difluoro-) 2-methylquinolin-3-yl)oxy]-6-fluorophenyl)propan-2-ol), (15,067) (5-bromo-1-(5,6-dimethylpyridin-3-yl)-3,3-dimethyl- 3,4-dihydroisoquinoline), (15,068) (3-(4,4-difluoro-5,5-dimethyl-4,5-dihydrothieno[2,3-c]pyridin-7-yl) quinoline), (15,069) (1-(4,5-dimethyl-1H-benzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline), (15,070) 8-fluoro-3-(5-fluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinolone, (15,071) 8-fluoro-3-(5-fluoro-3,3 ,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinolone, (15. 072) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydro-isoquinolin-1-yl)-8-fluoroquinoline, (15,073) (N-methyl-N-phenyl-4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide), (15,074) (methyl4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-ylphenyl )carbamate), (15,075) (N-(4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]benzyl)cyclopropanecarboxamide), (15,076) N-methyl-4-(5 -(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]benzamide, (15,077) N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-Oxadiazo|- 3-ylbenzamide, (15,078) N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]benzamide, (15,079) N-[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]cyclopropanecarboxamide, (15,080) N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]benzamide, (15,081) 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenylJacetamide, (15,082) N -allyl-N-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol|-3-yl)phenyl]Jmethyl]acetamide, (15,083) N-[(E)-N-methoxy-C -methyl-carbonimidoyl]-4-(5-(triflu- oromethyl)-1,2,4-Oxadiazol-3-yl]benzamide, (15,084) N-[(Z)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2 ,4-Oxadiazol-3-yl]benzamide, (15,085) N-allyl-N-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]phenyl]]methyl]

propanamide, (15,086) 4,4-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrrolidin-2-one, (15,087 ) N-methyl-4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]benzenecarbothioamide, (15,088) 5-methyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-Oxadiazol-3-yl]phenyl]methyl]pyrrolidin-2-0ne, — (15,089) N-((2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-Oxadiazole -3-yl]phenyl]Jmethyl]-3,3,3-trifluoro-propanamide, (15,090) 1-methoxy-1-methyl-3-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]!phenyl]methylJurea, (15,091) 1,1-diethyl-3-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]phenyl]JmethylJurea , (15,092) N-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]phenyl)|Mmethyl)|oropanamide, (15,093) N-methoxy-N-[[4- [5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]Yphenyl]Jmethyl|cyclopropanecarboxamide, (15,094) 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methylJurea, (15,095) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl ]phenyl]methyl)cyclopropanecarboxamide, — (15,096) N,2-dimethyl xi-N-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]phenyl]methyl]propanamide, (15,097) N-ethyl-2-methyl-N-[[ 4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-ylphenyl]methyl|propanamide, (15,098) 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methylJurea, (15,099) 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-0xadiazol-3 -yl]phenyl]methylJurea, (15,100) 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]Jmethyl]urea, ( 15,101) 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]Yphenyl] methylpiperidin-2-one, (15,102) 4,4-dimethyl-2-[[ 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyllyso-oxazolidin-3-one, (15,103) 5,5-dimethyl-2-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyllysoxazolidin-3-one, (15,104) 3,3-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole |-3-yl]phenyl]methyl]piperidin-2-one, (15,105) 1-[[3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methylJazepan-2-one, (15,106) 4,4-dimethyl-2-[[4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]lysoxazolidin-3-one and (15,107) 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-Oxadiazol-3-yl]phenyl]methyllysoxazolidin-3- one.

[00184] All named mixing partners of classes (1) to

(15), as described above herein, may be present in the form of the free compound and/or, if their functional groups permit, an agriculturally acceptable salt thereof.

[00185] —Isoflucypram can also be combined with one or more biological control agents.

[00186] Examples of biological control agents that can be combined with Isoflucypram are:

[00187] (A) Antibacterial agents selected from the group of:

[00188] (A1) bacteria such as (A1.1) Bacillus subtilis, in particular the strain QST713/AQ713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having Accession No. NRRL B21661 and described in US Patent No. 6,060,051); (A1.2) Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel'y from Certis, US, under accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); (A1.3) Bacillus pumilus, in particular the BU F-33 strain (with Accession No. NRRL 50185); (A1.4) Bacillus subtilis var. amyloliquefaciens strain FZB24 (available as TaegroO from Novozymes, US); (A1.5) a Paenibacillus sp. with NRRL Accession No. B-50972 or NRRL Accession No. B-67129 and described in International Patent Publication No. WO 2016/154297; and

[00189] (A2) fungi, such as (A2.1) Aureobasidium pullulans, in particular blastospores of the DSM14940 strain; (A2.2) Aureobasidium pullulans blastospores of the DSM 14941 strain; (A2.3) Aureobasidium pullulans, in particular mixtures of blastospores from strains DSM14940 and DSM14941;

[00190] (B)Biological fungicides selected in the group of:

[00191] (B1) bacteria, for example (B1.1) Bacillus subtilis, in particular strain QST713/AQ713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having Accession No.

NRRL B21661 and described in US Patent No. 6,060,051); (B1.2) Bacillus pumilus, in particular strain QST2808 (available as SONATAG from Bayer CropScience LP, US, having Accession No. NRRL B-30087 and described in U.S. Patent No. 6,245,551); (B1.3) Bacillus pumilus, in particular strain GB34 (available as Yield ShieldO from Bayer AG, DE); (B1.4) Bacillus pumilus, in particular the BU F-33 strain (with Accession No. NRRL 50185); (B1.5) Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel "Y from Certis, US, having accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); ) Bacillus subtilis Y1336 (available as BIOBACGO WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under registration Nos. 4764, 5454, 5096 and 5277); (B1.7) Bacillus amyloliquefaciens strain MBI 600 (available as SUBTILEX from BASF SE); B1.8) Bacillus subtilis strain GBO03 (available as Kodiak& from Bayer AG, DE); (B1.9) Bacillus subtilis var. amyloliquefaciens strain FZB24 (available from Novozymes Biologicals Inc., Salem, Virginia or Syngenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGROGP or TAEGROGO ECO (Redgistro EPA No. 70127-5); (B1.10) Bacillus mycoides, isolate J (available as BmJ TGAI or WG from Certis USA); (B1.11) Bacillus licheniformis, in particular strain SB3086 (available as EcoGuard TM Biofungicide and Green Releaf from Novo zymes); (B1.12) a Paenibacillus sp. strain having NRRL Accession No. B-50972 or NRRL Accession No. B-67129 and described in International Patent Publication No. WO 2016/154297.

[00192] In some embodiments, the biological control agent is a strain of Bacillus subtilis or Bacillus amyloliquefaciens that produces a fengycin or plipastatin-type compound, an iturine-type compound and/or a surfactin-type compound. For background information, see the following review article: Ongena, M,, et al., “Bacillus Li-

Popeptides: Versatile Weapons for Plant Disease Biocontrol,” (Bacillus Lipopeptides: Versatile Weapons for Plant Disease Biocontrol), Trends in Microbiology, Vol 16, No. 3, March 2008, pp. 115-125. Bacillus strains capable of producing lipopeptides include Bacillus subtilis QST713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having Accession No. NRRL B21661 and described in US Patent No. 6,060,051), Bacillus amyloliquefaciens cepa D747 (available as Double Nickel'y from Certis, US, accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); Bacillus subtilis MBI600 (available as SUBTILEX from Becker Underwood, US EPA Reg. No. 71840-8); Baci- Ilus subtilis Y1336 (available as BIOBACG WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registry Nos. 4764, 5454, 5096, and 5277); Bacillus amyloliquefaciens, in particular the FZB42 strain (available as RHIZOVITALO from ABITEP, DE); and Bacillus subtilis var. amyloliquefaciens FZB24 (available from Novozymes Biologicals Inc., Salem, Virginia or Syngenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGROGO or TAEGROGO ECO (EPA Registration No. 70127-5); and

[00193] (B2) fungi, for example: (B2.1) Coniothyrium minitans, in particular the CON/M/91-8 strain (Accession No. DSM-9660; for example, Contans& from Bayer); (B2.2) Metschnikowia fructicola, in particular the NRRL Y-30752 strain (eg Shemer&); (B2.3) Microsphaeropsis ochracea (for example, Microx6& from Prophyta); (B2.5) Trichoderma spp., including Trichoderma atroviride, strain SC1 described in International Application No. PCT/IT2008/000196); (B2.6) Trichoderma harzianum rifai strain KRL-AG2 (also known as strain T-22, IATCC 208479, e.g., PLANTSHIELD T-22G, RootshieldO and TurfShield from BioWorks, US); (B2.14) Gliocladium roseum, strain 321U from W.F. Stoneman Company LLC; (B2.35) Talaromyces flavus strain

V117b; (B2.36) Trichoderma asperellum, strain ICC 012 from Isagro; (B2.37) Trichoderma asperellum, strain SKT-1 (for example, ECO-HOPEQG from Kumiai Chemical Industry); (B2.38) Trichoderma atroviride, strain CNCM 1-1237 (eg, Esquive & WP from Agrauxine, FR); (B2.39) Trichoderma atroviride, strain no.

VO8/002387; (B2.40) Trichoderma atroviride, NMI strain no.

VO8/002388; (B2.41) Trichoderma atroviride, NMI strain no.

VO8/002389; (B2.42) Trichoderma atroviride, NMI strain no.

VO8/002390; (B2.43) Trichoderma atroviride, strain LC52 (for example, Tenet from Agrimm Technologies Limited); (B2.44) Trichoderma atroviride, strain ATCC 20476 (IMI 206040); (B2.45) Trichoderma atroviride, strain T11 (IMI352941 / CECT20498); (B2.46) Trichoderma harmatum; (B2.47) Trichoderma harzianum; (B2.48) Trichoderma harzianum rifai T39 (for example, Trichodex® from Makhteshim, US); (B2.49) Trichoderma harzianum, in particular KD strain (for example, Trichoplus from Biological Control Products, SA (acquired by Becker Underwood)); (B2.50) Trichoderma harzianum, strain ITEM 908 (for example, Trianum-P from Koppert); (B2.51) Trichoderma harzianum, strain TH35 (eg Root-Pro from Mycontrol); (B2.52) Trichoderma virens (also known as Gliocladium virens), in particular the GL-21 strain (eg SoilGard 12G from Certis, US); (B2.53) Trichoderma viride, strain TV1 (eg, Trianum-P from Koppert); (B2.54) Ampelomyces quisqualis, in particular the AQ 10 strain (for example, AQ 1006 from IntrachemBio Italia); (B2.56) Aureobasidium pullulans, in particular blastospores of the DSM14940 strain; (B2.57) Aureobasidium pullulans, in particular blastospores of the DSM 14941 strain; (B2.58) Aureobasidium pullulans, in particular mixtures of blastospores from strains DSM14940 and DSM 14941 (for example, Botector& from bio-ferm, CH); (B2.64) Cladosporium cladosporioides, strain H39 (by Stichting Dienst Landbouwkundig Onderzoek); B2.69) Gliocladium catenulatum (Synonym: Clonostachys rosea f.

Catenulate) strain J1446

(eg Prestop® from AgBio Inc. and also eg PrimastopO from Kemira Agro Oy); (B2.70) Lecanicillium lecanii (formerly known as Verticilium lecanii) conidia of the KVO1 strain (eg Vertalec& from Koppert/Arysta); (B2.71) Penicillium vermiculum; (B2.72) Pichia anomala, strain WRL-076 (NRRL Y-30842); (B2.75) Trichoderma atroviride, strain SKT-1 (FERM P-16510); (B2.76) Trichoderma atroviride, strain SKT-2 (FERM P-16511); (B2.77) Trichoderma atroviride, strain SKT-3 (FERM P-17021); (B2.78) Trichoderma gamsii (formerly T. viride), strain ICCO80 (IMI CC 392151 CABI, e.g. BioDerma by AGROBIOSOL DE MEXICO, S.A. DE C.V.); (B2.79) Trichoderma harzianum, strain DB 103 (for example, T-Gro 7456 from Dagutat Biolab); (B2.80) Trichoderma polysporum, IMI strain 206039 (for example, Binab TF WP from BINAB Bio-Ilnnovation AB, Sweden); (B2.81) Trichoderma stromaticum (eg Tricovab from Ceplac, Brazil); (B2.83) Ulocladium oudemansii, in particular the HRUS3 strain (for example Botry-ZenO from Botry-Zen Ltd, NZ); (B2.84) Verticillium albo-atrum (formerly V. dahliae), strain WCS850 (CBS

276.92; eg Dutch Trig of Tree Care Innovations); (B2.86) Verticillium chlamydosporium; (B2.87) mixtures of Trichoderma asperellum strain ICC 012 and Trichoderma gamsii strain ICC 080 (known product as, for example, BIO-TAM'Y from Bayer CropScience LP, US).

[00194] Other examples of biological control agents that can be combined with Isoflucypram are:

[00195] bacteria selected from the group consisting of Bacillus cereus, in particular B. cereus strain CNCM 1-1562 and Bacillus firmus strain |-1582 (CNCM accession number 1-1582), Bacillus subtilis strain OST 30002 (No. of NRRL accession B-50421), Bacillus thuringiensis, in particular B. thuringiensis subspecies israelensis (serotype H-14), strain AMG65-52 (ATCC Accession No. 1276), B. thuringiensis subsp. aizawai,

in particular strain ABTS-1857 (SD-1372), B. thuringiensis subsp. kurstaki strain HD-1, B. thuringiensis subsp. tenebrionis strain NB 176 (SD-5428), Pasteuria penetrans, Pasteuria spp. (Nematoide Rotylenchulus reniformis) -PR3 (ATCC Accession Number SD-5834), Streptomyces microflavus strain AQ6121 (= QRD 31.013, NRRL B-50550) and Streptomyces galbus strain AQ 6047 (Accession Number NRRL 30232);

Fungi and yeasts selected from the group consisting of Beauveria bassiana, in particular ATCC 74040 strain, Lecanicillium Spp., in particular HRO LEC 12 strain, Metarhizium anisopliae, in particular F52 strain (DSM3884 or ATCC 90448), Paecilomyces fumoso - roseus (now: Isaria fumosorosea), in particular strain IFPC 200613, or strain Apopka 97 (Accession No. ATCC 20874) and Paecilomyces lilacinus, in particular strain P. lilacinus 251 (AGAL 89/030550);

[00197] viruses selected from the group consisting of Adoxophyes orana (summer fruit tortrix) granulovirus (GV), Cydia pomonella (apple moth) granulovirus (GV), Helicoverpa armigera (cotton caterpillar) nuclear polyhedrosis virus ( nuclear polyhedrosis virus - NPV), Spodoptera exigua (beet worm) MNPV, Spodoptera frugiperda (cart worm) MNPV and Spodoptera littoralis (African cotton worm) NPV.

[00198] bacteria and fungi that can be added as “inoculants” to plants or parts of plants or plant organs and that, by virtue of their particular properties, promote the growth and health of plants. Examples are: Agrobacterium spp., Azorhizobium caulinodans, Azospirilum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderia cepacia (formerly known as Pseudomonasspora cepacia., Gigaspora spp.), or Gigaspora spp. monosporum, Glomus spp., Laccaria spp., Lactobacillus buchneri, Paraglomus spp., Pisolithus tinctorus, Pseudomonas spp., Rhizobium spp., in particular Rhizobium trifolii, Rhizopogon spp.,

Scleroderma spp., Suillus spp., and Streptomyces spp.

[00199] plant extracts and products formed by microorganisms, including proteins and secondary metabolites that can be used as biological control agents, such as Allium sativum, Artemisia absinthium, azadirachtin, Biokeeper WP, Cassia nigricans, Celastrus an- latus, Chenopodium anthelminticum, chitin, Armour-Zen, Dryopteris filixmas, Equisetum arvense, Fortune Aza, Fungastop, Heads Up (Chenopodium quinoa saponin extract), Pyrethrum/Pyrethrins, Quassia amara, Quercus, Quillaja, Regalia, "Regalia Insecticide Y", rotenone, rianial/ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, Triact 70, TriCon, Tropaeulum majus, Urtica dioica, Veratrin, Viscum album, Brassicaceae extract, in particular rape powder or mustard powder .

[00200] Examples of insecticides, acaricides and nematicides, respectively, that can be mixed with Isoflucypram are:

[00201] (1) Acetylcholinesterase (AChE) inhibitors, such as, for example, carbamates, for example alanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetacarb, isocarbenate, fura methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiophanox, triazamate, trimetacarb, XMC and xylylcarb; or organophosphate, for example acephate, azamethiphos, azinphos-eltil, azinphos-methyl, cadusaphos, chlorhexphos, chlorfenvinphos, chlormephos, chlorpyriphos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichloro-you/ dicrotophos, dimethoate, dimethylvinphos, disulfotone, EPN, ethion, ethoprophos, famfur, fenamiphos, fenitrothione, phenthione, phosthiazate, heptenophos, imicyaphos, isofenphos, O-(methoxyaminothiophosphoryl) salicylate, meta- thiophosphoryl, isoxathione, malo- thiosalicylate, isoxathione - na, mevinphos, monocrotophos, naled, omethoate, oxidemeton-methyl, pa- ration-methyl, phentoate, phorate, phosalone, phosmete, phosphamidone, foxim,

pyrimiphos-methyl, profenophos, propetamphos, prothiophos, pyraclophos, pyridafenthion, quinalphos, sulfotepe, tebupyrimphos, temephos, terbuphos, tetrachlorovinphos, thiomethon, triazophos, trichlorophon, vamidothione.

(2) GABA-dependent chloride channel blockers such as, for example, organochlorine-cyclodiene, for example chlordane and endosulfan or phenylpyrazoles (fiproles), for example ethiprole and fipronil.

(3) Sodium channel modulators such as, for example, pyro- roids, for example, acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin s-cyclopentenyl isomer , bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin [(1R)-trans -isomer], deltamethrin, empentrin [(EZ)-(1R)-isomer], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucitrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadetrin, momfluorothrin, phenothrin [(1R)-trans-isomer], pralethrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R) isomer], tralomethrin and transfluthrin or DDT or methoxychlor.

[00204] (4) competitive modulators of the nicotinic acetylcholine receptor (nAChR)), such as, for example, neonicotinoids, for example acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam or nicotine or sulfoxaflor or flupyradifurone.

[00205] (5) Allosteric modulators of the nicotinic acetylcholine receptor (nAChR) such as, for example, spinosyns, for example spinetoram and spinosad.

(6) Allosteric glutamate-dependent chloride channel (GluCl) modulators, such as, for example, avermectins/milbemycins, for example, abamectin, emamectin benzoate, lepimectin and milbectin.

[00207] (7) Juvenile hormone mimics such as, for example, juvenile hormone analogues, for example, hydroprene, quinoprene and methoprene or fenoxycarb or pyriproxyfen.

(8) Miscellaneous non-specific (multi-site) inhibitors, such as, for example, alkyl halides, for example, methyl bromide and other alkyl halides; or chloropicrin or sulfuryl fluoride or borax or tartar emetic or methyl isocyanate generators, for example dazomete and metam;

[00209] (9) modulators of cordotonal organs, such as, for example, pymetrozine or flonicamid;

[00210] (10) Inhibitors of the growth of mites, such as, for example, clofentezine, hethiazox and diflovidazine or etoxazol;

[00211] (11) Microbial disruptors of the intestinal membrane of the insect, such as, for example, Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subespecie, and proteins Bt vegetables: Cry1Ab, Cry1Ac, CryiFa, Cry1A.105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb, Cry34Ab1/35Ab1;

[00212] (12) Inhibitors of mitochondrial ATP synthase, such as ATP disruptors, such as, for example, diafentiuron or organotin compounds, for example, azocyclotin, cyhexatin and fembutatin oxide or propargite or tetradiphone;

[00213] (13) Oxidative phosphorylation uncouplers by means of proton gradient disruption, such as, for example, chlorfenapyr, DNOC and sulfluramid;

[00214] (14) Nicotinic acetylcholine receptor channel blockers, such as, for example,bensultape, cartape hydrochloride, thiocylam and thiosultapesodium;

(15) Inhibitors of chitin biosynthesis, type 0, such as, for example, bistrifluron, chlorfluazuron, diflubenzuron, flucicloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflu-benzuron and triflumuron;

[00216] (16) Inhibitors of chitin biosynthesis, type 1, for example buprofezin;

[00217] (17) Moult disruptor (in particular for Diptera, ie Diptera), such as cyromazine;

[00218] (18) Ecdysone receptor agonists such as, for example, chromafenozide, halofenozide, methoxyfenozide and tebufenozide;

[00219] (19) Octopamine receptor agonists such as, for example, amitraz;

[00220] (20) Inhibitors of the electron transport of the mitochondrial III complex, such as, for example, hydramethylnon or acequinocil or fluacripyrim;

[00221] (21) Complex electron transport inhibitors | mitochondrial, such as, for example, from the group of the METI acaricides, for example phenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris);

[00222] (22) Voltage-dependent sodium channel blockers, such as indoxacarb or metaflumizone;

[00223] (23) Inhibitors of acetyl CoA carboxylase, such as, for example, derivatives of tetronic and tetramic acid, for example, spirodiclophen, spiromesifen and spirotetramate;

[00224] (24) Inhibitors of mitochondrial complex IV electron transport, such as, for example, phosphines, for example aluminum phosphide, calcium phosphide, phosphine and zinc phosphide or cyanides, for example, calcium cyanide, calcium cyanide potassium and sodium cyanide;

[00225] (25) Inhibitors of the electron transport of the mitochondrial complex, such as, for example, beta-cetonitrile derivatives, for example, cyenopyrafem and ciflumetofen and carboxanilides, such as, for example, piflubumide;

[00226] (28) Rianodine receptor modulators, such as, for example, diamides, for example, chlorantraniliprole, cyantraniliprole and flubendiamide,

[00227] other active compounds such as, for example, afidopyropen, afoxolaner, azadirachtin, benclothiaz, benzoximate, biphenazate, broflanilide, bromopropylate, quinomethionate, chlorpralethrin, cryolite, cyclanyl-prol, cycloxapride, cyanodiazole, methioniamide, dichlorome , epsilon-momfluthrin, flomethoquin, fluazaindolizine, fluensulfone, flufenerim, flufenoxystrobin, flufiprol, flunexafon, fluopyram, fluralaner, fluxametamide, fufenozide, guadipyr, heptafluthrin, imidaclotiz, loti-fluthir, cappa-flunerdione, - trin, paichongding, pyridalyl, pyrifluquinazone, pyriminostrobin, spirodiclofen, tetramethylfluthrin, tetraniliprol, tetrachlorantraniliprole, tigolaner, thioxazafen, thiofluoximate, triflumezopyrim and iodomethane; in addition to preparations based on Bacillus firmus (1-1582, BioNeem, Votive); and the following compounds: 1-(2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinylphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5 -amine (known from WOZ2006/043635) (CAS 885026-50-6), (1'-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indole -3,4'-piperidin]-1(2H)-yl)(2-chloropyridin-4-yl)methanone (known from WOZ2003/106457) (CAS 637360-23-7), 2-chloro-N-[2 -(1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl)-4-(trifluoromethyl)phenyllysonicotinamide (known from WO2006/003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diaza-pyro[4.5]dec-3-en-2-o0ne (known of WO 2010052161) (CAS 1225292-17-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-2-0x0-1,8-diaza-pyro[4.5]dec-3-en -4-yl ethyl carbonate (known from EP2647626) (CAS 1440516-42-6), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5- fluoropyrimidine (known from WO2Z2004/099160) (CAS 792914-58-0), PF1364 (known from JP2010/018586) (CAS 1204776-60-2), N-[(2E)-

1-[(6-chloropyridin-3-yl)methyl]pyridin-2(1H)-ylidene]-2,2,2-trifluoroacetamide (known from WO2012/029672) (CAS 1363400-41-2), (3E) -3-[1-[(6-chloro-3-pyridyl)|methyl]-2-pyridylidene]-1,1,1-trifluoro-propan-2-one (known from WO2013/144213) (CAS 1461743 -15-6), N-[3-(benzylcarbamoyl)-4-chlorophenyl]-1-methyl-3-(pentafluoroethyl)-4-(trifluoromethyl)-1H-pyrazol-5-carboxamide (known from WO2010/051926) (CAS 1226889-14-oO), 5-bromo-4-chloro-N-[4-chloro-2-methyl-6-(methylcarbamoyl)phenyl]-2-(3-chloro-2- pyridyl)pyrazole-3-carboxamide (known from CN103232431) (CAS 1449220-44-3), 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-S5-(trifluoromethyl)- 3-isoxazolyl])-2-methyl-N-(cis-1-oxide-3-thiethanyl)-benzamide, 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-S5-( trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(trans-1-oxide-3-thiethanyl)-benzamide and 4-[(58)-5-(3,5-dichlorophenyl)-4,5-di -hydro- B-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(cis-1-oxide-3-thiethanyl)benzamide (known from WO 2013/050317 A1) (CAS 1332628-83-7 ), N-[ 3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamide, (+)-N-[3 -chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamide and (-)-N-[3- chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamide (known from WO 2013/162715 A2, WO 2013/162716 A2, US 2014/0213448 A1) (CAS 1477923-37-7), 5-[[(2E)-3-chloro-2-propen-1-yl]amino]-1-[2 ,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (known from CN 101337937 A) (CAS 1105672-77-2), 3-bromo -N-[4-chloro-2-methyl-6-[(methylamino)thioxomethyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazol-5-carboxamide, (Liudaibenjiaxuanan, aka CN 103109816 A) (CAS 1232543-85-9); N-[4-chloro-2-[[(1,1-dimethylethyl)amino]carbonyl]-6-methylphenyl]-1-(3-chloro-2-pyridinyl)-3-(fluoro-methoxy)-1H- Pyrazole-5-carboxamide (known from WO 2012/034403 A1) (CAS 1268277-22-0), N-[2-(5-amino-1,3 4-thiadiazol-2-yl)-4-chloro-6 - methylphenyl]-3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazol-5-carboxamide (known from WO 2011/085575 A1) (CAS 1233882-22-8), 4-[3- [2,6-

dichloro-4-[(3,3-dichloro-2-propen-1-yl)oxylphenoxypropoxy]-2-methoxy-6-(trifluoromethyl)-pyrimidine (known from CN 101337940 A) (CAS 1108184-52-6 ); (2E)- and 2(Z)-2-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenylJethylidene]-N-[4-(difluoromethoxy)phenyl]hydrazinecarboxamide (known from CN 101715774 A ) (CAS 1232543-85-9); 3-(2,2-dichloro-ethenyl)-2,2-dimethyl-4-(1H-benzimidazol-2-ylYphenyl-cyclopropanecarboxylic acid ester (known from CN 103524422 A) (CAS 1542271-46-4); ester (4aS)-7-chloro-2,5-dihydro-2-[[(methoxycarbonyl)[4-[(trifluoromethyl)thio]phenyl]amino]carbonyl]-indeno[1,2-e] acid methyl [1,3,4Joxadiazine-4a(3H)-carboxylic (known from CN 102391261 A) (CAS 1370358-69-2); 6-deoxy-3-O-ethyl-2,4-di-O-methyl-, 1-[N-[4-[1-[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-1H-1,2,4-triazol-3-yl]phenyl|carbamate]-aL -mannopyranose (known from US 2014/0275503 A1) (CAS 1181213-14-8); 8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl )-3-aza-bicyclo[3.2.1 Joctan (CAS 1253850-56-4), (8-anti)-8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin- 3-i1)-3-aza-bicyclo[3.2.1]octane (CAS 933798-27-7), (8-syn)-8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-( 6-trifluoromethyl-pyridazin-3-yl)-3-aza-bicyclo[3.2.1]octane (known from WO 2007040280 A1 , WO 2007040282 A1) (CAS 934001-66-8), - N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3 ,3-trifluoropropyl)thio)-propanamide (known from WO 2015/058021 A1, WO 2015/058028 A1) (CAS 1477919-27-9) and N-[4-(aminothioxomethyl)-2-methyl-6-[( methylamino)carbonyl]phenyl]-3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide (known from CN 103265527 A) (CAS 1452877-50-7), 5-( 1,3-dioxan-2-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]pyrimidine (known from WO 2013/115391 A1) (CAS 1449021-97-9), 3-(4-chloro -2,6-dimethylphenyl)-4-hydroxyl-8-methoxy-1-methyl-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO 2010/066780 A1, WO 2011/151146 A1) (CAS 1229023-34-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-1,8-diazaspiro[4.5]decane-2,4-dione (known of WO 2014/187846

A1) (CAS 1638765-58-8), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-2-0x0-1,8-diazaspiro[4.5] acid ethyl ester ]dec-3-en-4-yl-carbonic (known from WO 2010/066780 A1, WO 2011151146 A1) (CAS 1229023-00-0), N-[1-[(6-chloro-3-pyridinyl )methyl]-2(1H)-pyridinylidene]-2,2,2-trifluoro-acetamide (known from DE 3639877 A1, WO 2012 029672 A1) (CAS 1363400-41-2), [N(E)]-N -[1-[(6-chloro-3-pyridinyl)|]methyl]-2(1H)-pyridinylidene]-2,2,2-trifluoro-acetamide, (known from WO 2016005276 A1) (CAS 1689566-03- 7), [N(Z)]-N-[1-[(6-chloro-3-pyridinyl)methyl]-2(1H)-pyridinylidene]-2,2,2-trifluoro-acetamide, (CAS 1702305- 40-5), 3-endo-3-[2-propoxy-4-(trifluoromethyl)phenoxy]-9-[[5-(trifluoromethyl)-2-pyridinyloxy]-1-9-azabicyclo[3.3.1.-nonane (known from WO 2011/105506 A1, WO 2016/133011 A1) (CAS 1332838-17-1).

[00228] “Examples of safeners that can be mixed with Isoflucypram are, for example, benoxacor, cloquintocet (-mexil), ciometrinil, cyprosulfamide, dichlormid, fenchlorazol (-ethyl), phenchlorim, flurazol, flurazol, flurazol , furilazole, isoxadiphene (-ethyl), mefenpyr (-diethyl), naphthalic anhydride, oxabetrinyl, 2-methoxy-N-(f4-[(methylcarbamoyl)amino]phenyl)sulfonyl)benzamide (CAS 129531-12-0), 4 -(dichloroacetyl)-1-oxa-4-azaspiro[4.5)decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine (CAS 52836- 31-4).

[00229] "Examples of herbicides that can be mixed with Isoflucypram are:

[00230] acetochlor, acifluorfen, acifluorfen-sodium, —aclonifem, alachlor, alidochlor, aloxidim, aloxidim-sodium, ametrine, amicarbazone, amidochlor, amidosulfuron, acid 4-amino-3-chloro-5-fluoro-6-(7- fluoro-1H-indol-6-yl)pyridine-2-carboxylic, aminocyclopyrachlor, aminocyclopyrachlor-potassium, aminocyclopyrachlor-methyl, aminopyralide, amitrol, ammonium sulfamate, anilophos, asulam, atrazine, azafenidine, azinsulfuron, beflubutamide, benazolin, benazolin-ethyl, benfluralin, benfuresate, bensulfuron, bensulfuron-methyl,bensulide, bentazone,

benzobicyclom, benzofenape, bicyclopyrone, bifenox, bilanafos, bilanophos-sodium, bispyribak, bispyribaque-sodium, bixlozone, bromacil, bromobutide, bromophenoxym, bromoxynyl, bromoxynyl butyrate, bromoxynyl-hexaxyn-potatinyl-butyrate busoxinone, butachlor, butaphenacil, butamiphos, butenachlor, butralin, butroxydim, butylate, cafenstrol, carbetamide, carfentrazone, carfentrazone-ethyl, chloramben, chlorbromuron, chlorfenac, chlorfenac-sodium, chlorfenchloren-prope, chlorfluride chlorimuron, chlorimuron-ethyl, 2-[2-chloro-4-(methylsulfonyl)-3-(morpholin-4-ylmethyl)benzoyl)-3-hydroxycyclohex-2-en-1-one, 4-(2- chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)mMethylbenzoyl)-1-ethyl-1H-pyrazol-5-yl-1,3-dimethyl-1H,pyrazole-4-carboxylate, chlorophthalim , chlorotoluron, chlorthal-dimethyl, 3-[5-chloro-4-(trifluoromethyl)pyridine-2-yl]-4-hydroxy-1-methylimidazolidin-2-one chlorsulfuron, cinidone, cinidone-ethyl, cinme tilin, cinosulfuron, clakiphos, clethodim, clodinafop, clodinafop-propargyl, clomazone, clomeprop, clopyralide, chloransulam, chloransulam-methyl, cumilurone, cyanamide, cyanazine, cycloate, cyclodipyranil, cyclosophya-murium, cyclopyrimate cylofop-butyl, cyprazine, 2,4-D, 2,4-D-butyl, -butyl, -dimethylammonium, diolamine, -ethyl, -2-ethyl-hexyl, iso-butyl, -iso-octyl, -isopropylammonium, -potassium, -tri-isopropanolammonium, and -trolamine, 2,4-DB, 2,4-DB-butyl, -dimethylammonium, -iso-octyl, -potassium, and -sodium, daimuron (dimrone), dalapone, dazomete, n-decanol, desmedipham, detosyl-pyrazolate (DTP), dicamba, dichlobenyl, 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, 2-( 2,5-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, dichlorprop, dichlorprop-P, diclofop, diclofop-methyl, diclofop-P-methyl, diclosulam, difenzoquat, diflufenicam, diflufenzopyr , diflufenzopyr-sodium, dimefurone, dimepiperate, dimethachlor, dimethametrine, dimethenamid, dimethenamid-P, 3-(2,6-dimethylphenyl)-6-[(2-hydroxy-6-oxocyclohex-1-en-1-yl)carbonyl]-1-methylginazolin-2,4 (1H ,3H)-dione, — 1,3-dimethyl-4-[2-(methylsulfonyl)-4-(trifluoromethyl)benzoyl]-

1H-pyrazol-5-yl-1,3-dimethyl-1H-pyrazol-4-nitrobenzoate, SYP-300, ie 1-[7-fluoro-3-0x0-4-(prop-2-yn-1-yl )-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-3-propyl-2-thioxoimidazolidine-4,5-dione, 2,3,6-TBA, TCA (trichloroa-acid- skeptical), TCA-sodium, tebutiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbumetone, terbuthylazine, terbutryn, tetflupyrolimet tenilchlor, thiazopyr, thiencarbazone, thiencarbazone-methyl, tifen-thiophenacilyl, sulfenomethyl, thifen tolpyralate, topramezone, tralkoxydim, triaphamon, triallate, triasulfuron, triaziflam, tribenuron, tribenuron-methyl, triclopyr, triethazine, trifloxysulfuron, trifloxysulfuron-sodium, trifludimoxazine, trifluralin, triflumethylic, trisulfuron-sulfuron, triflurosulfuron -848, ZJ-0862, ie 3,4-dichloro-N-(2-[(4,6-dimethoxypyrimidin-2-yl)oxylbenzyl)aniline

[00231] "Examples of plant growth regulators are:

[00232] acibenzolar, acibenzolar-S-methyl, 5-aminolevulinic acid, ancimidol, 6-benzylaminopurine, Brassinolide, catechin, chlormequat chloride, cloprop, cyclanilide, 3-(cycloprop-1-enyl)propionic acid, daminozide, dazomete, n-decanol, dikegulac, dikegulac-sodium, endothal, endothal-dipotassium, disodium, and -mono (N,N-dimethylalkylammonium), ethephon, flumetralin, flurenol, flurenol-butyl, flurprimidolurom, for- , gibberellic acid, inabenfide, indole-3-acetic acid (IAA), 4-indol-3-yl butyric acid, isoprothiolane, probenazol, jasmonic acid, maleic hydrazide, mepiquat chloride, 1-methylcyclopropene, methyl jasmonate, 2-(1-naphthyl) acetamide, 1-naphthylacetic acid, 2-naphthyloxyacetic acid, nitrophenolate mixture, paclobutrazol, N-(2-phenylethyl)-beta-alanine, N-phenylphthalamic acid, prohexadione, prohexadione-calcium, pro- hydrojasmone, salicylic acid, strigolactone, technazene, tidiazuron, triacontanol, trinexapaque, trinexapaque-ethyl, tsitodef, u niconazol, uniconazol-P.]

[00233] According to the invention, the expression "combination" re-

presents the various combinations of compounds (A) and (B), for example, in a single "ready mix" form, in a combined spray mix made up of separate formulations of the single active compounds, as a "tank mix" ”, and in a combined use of the single active ingredients when applied sequentially, that is, one after the other in a reasonably short period, such as a few hours or days. Preferably, the order of application of compounds (A) and (B) is not essential to the functioning of the present invention.

[00234] "In the combinations according to the invention, the compounds (A) and (B) may be present in a wide range of effective weight ratio of A:B, for example, in a range of 5000:1 to 1 :5000, preferably in a weight ratio of 1000:1 to 1:1000, more preferably in a weight ratio of 500:1 to 1:500, and most preferably in a weight ratio of 100:1 to 1: 100.

[00235] Other ratios of A:B that can be used in accordance with the present invention are: 95:1 to 1:95, 90:1 to 1:90, 85:1 to 1:85, 80:1 to 1 :80, 75:1 to 1:75, 70:1 to 1:70, 65:1 to 1:65, 60:1 to 1:60, 55:1 to 1:55, 50:1 to 1:50 , 45:1 to 1:45, 40:1 to 1:40, 35:1 to 1:35, 30:1 to 1:30, 25:1 to 1:25, 20:1 to 1:20, 15 :1 to 1:15, 10:1 to 1:10, 5:1 to 1:5.4:1 to 1:4, 3:1 to 1:3,2:1 to 1:2.

[00236] Other ratios of A:B that can be used in accordance with the present invention are: 1000:1 to 1:1, 500:1 to 1:1, 250:1 to 1:1, 100:1 to 1 :1, 95:1 to 1:1, 90:1 to 1:1, 85:1 to 1:1, 80:1 to 1:1,75:1 to 1:1, 70:1 to 1:1 , 65:1 to 1:1, 60:1 to 1:1, 55:1 to 1:1, 50:1 to 1:1, 45:1 to 1:1, 40:1 to 1:1, 35 :1 to 1:1, 30:1 to 1:1, 25:1 to 1:1, 20:1 to 1:1, 15:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1.4:1 to 1:1, 3:1 to 1:1.2:1 to 1:1.

[00237] Other ratios of A:B that can be used in accordance with the present invention are: 1:1 to 1:1000, 1:1 to 1:500, 1:1 to 1:250, 1:1 to 1 :100, 1:1 to 1:95, 1:1 to 1:90, 1:1 to 1:85, 1:1 to 1:80, 1:1 to

1:75, 1:1 to 1:70, 1:1 to 1:65, 1:1 to 1:60, 1:1 to 1:55, 1:1 to 1:50, 1:1 to 1: 45, 1:1 to 1:40, 1:1 to 1:35, 1:1 to 1:30, 1:1 to 1:25, 1:1 to 1:20, 1:1 to 1:15, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:4, 1:1 to 1:3, 1:1 to 1:2.

[00238] In another modality, isoflucypram may be present in its commercially available formulations and in forms of use, prepared from these formulations, as a mixture with one or more active ingredients selected from the group of fluopiram, prothioconazole, tebuconazole, epoxiconazole, difenoconazole, fluquinconazole, fluxapyroxad, flutriafol, azoxystrobin, trifloxystrobin, fluoxastrobin, fludioxonil, ipfentrifluconazole, metalaxyl, mefenoxam, mefentrifluconazole, pyraclostrobin, pyrimethanil, chlorthalonil, seda- loxa- nil, spiroxamine isopyrazam, metrafenone, broflanilide, imidacloprid, clothianidin, thiacloprid, thiamethoxam, rinaxapyr, cyazypyr, spirotetramate, spiromesiphen, tetraniliprol, flubendiamide, cyclaniliprol, lambda-cyhalothrin, fluazine, methyltetrapoleam.

Particularly preferred are prothioconazole or tebuconazole.

[00240] In a particular embodiment, isoflucypram is used as a mixture with prothioconazole or tebuconazole.

[00241] The use of isoflucypram mixed with prothioconazole or tebuconazole is preferably carried out with a dosage between 0.001 and 1 kg of isoflucypram/ha, between 0.01 and 3 kg of prothioconazole or tebuconazol/ha; more preferably between 0.002 and 0.5 kg of isoflucypram/ha, between 0.025 and 1 kg of prothioconazole or tebuconazole/ha; more preferably between 0.005 and 0.4 kg of isoflucypram/ha, between 25 and 400 g of prothioconazole or tebuconazole/ha; even more preferably between 7 and 150 g of isoflucypram/ha, between 25 and 400 g of prothioconazol or tebuconazol/ha most preferably between 10 and 120 g of isoflucypram/ha, between 40 and 400 g of prothioconazole or tebuconazole/ha.

A dosage of 15 to 100 g of Isoflucypram/ha and 60 to 300 g of protioconazole or tebuconazole/ha, more preferably 20 to 70 g of isoflucypram/ha and 60 to 300 g of prothioconazole or tebuconazol/ha, also - is well publicized. In another embodiment, the dosage is between 40 and 150 g of isoflucypram/ha and 60 to 240 g of prothioconazole or tebuconazole/ha; preferably between 30 and 120 g of isoflucypram/ha and 60 to 200 g of prothioconazole or tebuconazole/ha; more preferably between 25 and 100 g of isoflucypram/ha and 60 to 180 g of prothioconazole or tebuconazol/ha, most preferably between 20 and 90 g of isoflucypram/ha and 60 to 180 g of prothioconazol or tebuconazol/ha .

[00242] In another modality, isoflucypram is used as a mixture with prothioconazole and tebuconazole.

[00243] The use of isoflucypram mixed with prothioconazole and tebuconazole is preferably carried out with a dosage between 0.001 and 1 kg of isoflucypram/ha, between 0.01 and 3 kg of prothioconazole/ha, between 0.01 and 3 kg of tebuconazole/ha; more preferably between 0.002 and 0.5 kg of isoflucypram/ha, between 0.025 and 1 kg of prothioconazol/ha, between 0.025 and 1 kg of tebuconazol/ha; more preferably between 0.005 and 0.4 kg of isoflucypram/ha, between 25 and 400 g of prothioconazol/ha, between 25 and 400 g of tebuconazol/ha; even more preferably between 7 and 150 g of isoflucypram/ha, between 25 and 400 g of prothioconazol/ha, between 25 and 400 g of tebuconazol/ha; at most preferably between 10 and 120 g of isoflucypram/ha, between 40 and 400 g of protioconazol/ha, between 40 and 400 g of tebuconazol/ha. A dosage of 15 to 100 g of isoflucypram/ha, 60 to 300 g of prothioconazol/ha and 60 to 300 g of tebuconazol/ha, more preferably 20 to 70 g of isoflucypram/ha, 60 to 300 g of prothioconazol/ha and 60 to 300 g of tebuconazole/ha are also disclosed.

[00244] In another modality, the dosage is between 40 and 150 g of isoflucypram/ha, between 60 and 240 g of prothioconazole/ha and between 60 and 240 g of tebuconazol/ha; preferably between 30 and 120 g of isoflucypram/ha, between 60 and 200 g of prothioconazole/ha and between 60 and 200 g of tebuconazol/ha; more preferably between 25 and 100 g of isoflucypram/ha, between 60 and 180 g of prothioconazol/ha and between 60 and 180 g of tebuconazol/ha, most preferably between 20 and 90 g of isoflucypram/ha , between 60 and 180 g of prothioconazole/ha and between 60 and 180 g of tebuconazole/ha.

[00245] In a particular embodiment, isoflucyipram is used as a mixture containing fluazinam and/or methyltetrapole. In a particular modality, isoflucypram is used as a mixture with fluazinam or methyltetrapole.

[00246] The use of isoflucypram as a mixture with fluazinam or methyltetrapole is preferably carried out with a dosage between 0.001 and 1 kg of isoflucypram/ha, between 0.01 and 3 kg of fluazinam or methyltetrapole/ha; more preferably between 0.002 and 0.5 kg of isoflucypram/ha, between 0.025 and 1 kg of fluazinam or methyltetrapole/ha; more preferably between 0.005 and 0.4 kg of isoflucypram/ha, between 25 and 400 g of fluazinam or methyltetrapole/ha; even more preferably between 7 and 150 g of isoflucypram/ha, between 25 and 400 g of fluazinam or methyltetrapole/ha; at most preferably between 10 and 120 g of isoflucypram/ha, between 40 and 400 g of fluazinam or methyltetrapole/ha. A dosage of 15 to 100 g of isoflucypram/ha and 60 to 300 g of fluazinam or methyltetrapole/ha, more preferably 20 to 70 g of isoflucypram/ha and 60 to 300 g of fluazinam or methyltetrapole/ha, are also disclosed .

[00247] In another modality, the dosage is between 40 and 150 g of isoflucypram/ha and 60 to 240 g of fluazinam or methyltetrapole/ha; preferably between 30 and 120 g of isoflucypram/ha and 60 to 200 g of fluazinam or methyltetrapole/ha; more preferably between 25 and 100 g of isoflucypram/ha and 60 to 180 g of fluazinam or methyltetrapole/ha, most preferably between 20 and 90 g of isoflucypram/ha and 60 to 180 g of fluazinam or methyltetrapole/ha.

[00248] In a particular embodiment of the invention, isoflucypram is not employed in combination with fenpicoxamide.

[00249] In another particular embodiment of the invention, isoflucypram is not employed in a ternary combination with (B) fenpicoxamide and (C) another compound selected from prothioconazole, fluopyram and tebuconazole.

[00250] In another particular embodiment of the invention, isoflucypram is not employed in a ternary combination with (B) prothioconazole and (C) another compound selected from trifloxystrobin, tebuconazole or fluopiram.

[00251] The following example serves to illustrate the invention, but without restricting it Example 1

[00252] In Canada, in 2017, a test batch was run with the CTC Utmost spring wheat variety. Isoflucypram, as well as commercial standards, were applied on July 7, 2017 according to table 1 by foliar application, between BBCH stages 59 and 61. Sclerocia evaluation was carried out in autumn 2017 96 days after application.

&

E 8 8 and É sé o É | 2 sz e Ne vo o =) N F o Ss = Ss = 2 x E ? = ? - - the |.

o —=— SS: $ | o Õ E |O E Cc o OE 8 0 ia o > 2 5% 2 Oo jo Z o 2 jo É Fr o 6 o o o o? 2 niIF E = O | É E o SS o a = o Z2> = = N N 7 or N SB ES m > c£ r g 82 + Z o FE dd gE F & NR a 8 & Pó eÊE| AND IS? 2 2EZ| 6 2 | és o = le TF le cc Oo SE & £ |£ IS EE S5S|OS e& 8 > 2 BSS an ST à 8: 8 à SS IN THIS 2 jo & Ss & je SIS SIS SIA a o 2 2 & E e | 2 |S oo <£ - Tl HSE = => 3 8 = oo Ô o O reads, NS Not So - - -) Pr o = [a Ss 8Ss Is 8 o 1g>2 õ E le & & e 2 |3 so = - = S 3 is Sel s/a ES | 68 s o 8 e 8 = lo> a P - Õ 2 o Sw o A A 8 2 O 2 o Ss & RB E SD O n o o S ff S sv Z o “| > wW + —| + W V o Cs a Z O Fr o o El, o = 3 uU|> > 2 2 2 is EXE o = E| |O Ss wu E < a n& Oi O o 92 ilH 8 > Dx Nx N TE o õ õ 8 BEBSº | — SET AND [| It's 3 3BóB3SÍZIS o | o z REoprw oo o 6 2/2 2 | oooojpovia gi Eejz o 2 RE PE ZIOS

Claims (15)

1. Use of the fungicide Isoflucypram, characterized by the fact that it is for the control of Claviceps purpurea and/or reduction of Claviceps purpurea sclerotia in cereals. 2. Use according to claim 1, characterized in that Isoflucypram is applied as a foliar treatment to cereal plants. 3. Use according to claim 1, characterized in that Isoflucypram is applied as a foliar treatment to cereal plants on or after BBCH 50. 4. Use according to any one of claims 1 to 3, characterized in that Isoflucypram is applied as a foliar treatment at a rate of 2 to 500 g per hectare. 5. Use according to any one of claims 1 to 3, characterized in that Isoflucypram is applied as a foliar treatment at a rate of 10 to 120 g per hectare. 6. Use according to any one of claims 1 to 5, characterized in that the cereal plant is wheat, barley, rye, triticale or durum. 7. Use according to any one of claims 1 to 6, characterized in that the cereal plant is wheat. 8. Use according to any one of claims 1 to 7, characterized in that the cereal plant is hybrid wheat. 9. Use according to any one of claims 1 to 8, characterized in that Isoflucypram is used in combination with another active fungicide ingredient. 10. Use according to any one of claims 1 to 9, characterized in that Isoflucypram is used in combination with Protioconazole or Tebuconazole. 11. Use according to any one of claims 1 to 9, characterized in that Isoflucypram is used in combination with Protioconazole and Tebuconazole. 12. Use of Isoflucypram, characterized in that it is for the preparation of a composition for the control of Claviceps purpurea and/or reduction of Claviceps purpurea sclerotia in cereal plants. 13. Combinations for the control of Claviceps purpurea in cereal plants, characterized by the fact that they comprise Isoflucypram and another fungicide. 14. Compositions for the control of Claviceps purpurea in cereal plants, characterized by the fact that they comprise Isoflucypram and agriculturally suitable auxiliaries, solvents, carriers, surfactants or extenders. 15. Plants, parts of plants and/or seeds resistant to Claviceps purpurea, characterized in that they comprise plants, parts of plants and/or seeds coated with a combination, as defined in claim 13, a composition, as de- defined in claim 14, or Isoflucypram fungicide.